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ABSTRACT
Neural stem/progenitor cells (NPC) can be used for therapeutic purposes in several ways.
Cultured NPCs offer a unique cell source to study the neural mechanisms in normal
situations as well as in the pathogenesis of genetic diseases. In neurodegenerative
disorders, potential therapies to recover the damaged neurons are NPC transplantation or
activation of a patient’s own NPCs. However, the mechanisms of NPC differentiation are
still poorly known and before any clinical use, it is of utmost importantance to know how
the differentiation of NPCs is regulated. These four studies provide new information about
the differentiation of NPCs. Fragile X syndrome (FXS) is caused by the defiency of fragile X
mental retardation protein (FMRP). We investigated how FMRP deficiency affects the
differentiation of NPCs. We show that FMRP deficiency directs the NPC differentiation into
neuronal phenotypes, but developing neurons have fewer and shorter neurites and smaller
body volume. Furthermore, FMRP deficient NPCs have increased occurrence of intense
oscillatory Ca2+ responses to neurotransmitters (NT) compared to controls. In the second
study, we used Ca2+ imaging techniques to monitor the neurotransmitter responsiveness in
an early state of NPC differentiation. We found that during the early stage of
differentiation, cells responded to various NTs and could be distinguished based on their
NT responses. During development, cells progressively lose their metabotropic responses
and gain ionotropic responses while they simultaneously develop into neuronal cells. Next,
we  studied  the  effect  of  Alzheimer’s  disease  (AD)  -linked  mutation  and  environment  on
NPC differentiation. We treated NPCs with synthetic amyloid-? (A?) in vitro and also
transplanted NPCs into AD-linked mutant mouse brain. We show that both AD-linked
mutation in NPCs and AD-brain environment have effects on NPC differentiation.
Transplanted NPCs survived and migrated better when transplanted into AD mouse brain.
In addition, transplanted NPCs stimulated brain neurogenesis even in highly A?-burdened
brain. Oxidative stress (OS) is one of main characteristics in AD brain. Activation of a
transcription factor nuclear factor erythroid 2-related factor (Nrf2) during the OS leads to
activation of cellular defense mechanisms. We also show that the activation of Nrf2 protects
NPCs against A?-induced toxicity by enhancing their survival, proliferation and neuronal
differentiation. Furthermore, we discovered another important function for Nrf2: the ability
to regulate injury-induced neurogenesis.
National Library of Medical Classification: WL 102, QV 126
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TIIVISTELMÄ
Hermoston kantasoluja voidaan kasvattaa laboratoriossa. Neurosfeereinä eli eräänlaisina
hermokantasolupallosina kasvavat hermoston kantasolut tarjoavat työkalun tutkia
hermosolun erilaistumista. Geneettisesti muunnelluilla kantasoluilla voidaan tutkia kuinka
geenivirhe vaikuttaa kantasolujen erilaistumiseen. Lisäksi hermoston kantasolut voivat
tarjota mahdollisuuden hoitaa vaikeita hermorappeumasairauksia viljeltyjä hermoston
kantasoluja solusiirteenä käyttämällä tai aktivoimalla potilaan omia jo olemassa olevia
kantasoluja korvaamaan tuhoutuneita hermosoluja. Jotta hermoston kantasoluja voitaisiin
käyttää terapeuttisiin tarkoituksiin, täytyy ensin ymmärtää kuinka erilaistuvaa hermosolua
säädellään sekä miten geenivirheet ja sairauden patologia vaikuttavat kehittyviin
hermosoluihin. Tämän väitöstutkimuksen tarkoituksena oli tuottaa tietoa hermoston
kantasolujen erilaistumisesta. Tutkimme säätelevätkö klassiset hermovälittäjäaineet
hermoston kantasoluja ja miten kehitysvammaisuutta aiheuttavaan Fragile X oireyhtymään
(FXS) liittyvän fmr1-geenin mutaatio, joka johtaa FMR-proteiinin (FMRP) puutteeseen
vaikuttaa hermoston kantasolujen erilaistumiseen. Lisäksi tutkimme miten Alzheimerin
taudin (AT) patologia ja geenivirhe vaikuttavat hermoston kantasolujen erilaistumiseen ja
suojaako transkriptiotekijä Nrf2:n aktivaatio erilaistuvia hermoston kantasoluja amyloidi-?
(A?) -peptidin toksisilta vaikutuksilta. Tutkimuksemme osoitti, että solut, joilta puuttui
FMRP, erilaistuvat useammin neuroneiksi, joiden sooma oli pienempi ja joilla oli
vähemmän ja lyhyempiä neuriitteja kuin kontrollisoluilla. Lisäksi suurempi joukko
erilaistuvia soluja reagoi hermovälittäjäainestimulaatioon tuottamalla solunsisäisen
kalsiumpitoisuuden oskillaatioita. Kalsiumkuvannuksen avulla osoitimme, että erilaistuvat
hermosolut reagoivat monien hermovälittäjäaineiden stimulaatioon, joka tarkoittaa sitä,
että välittäjäaineet osallistuvat hermosolujen erilaistumisen säätelyyn. Kolmannessa
tutkimuksessa havaitsimme että sekä AT:n patologia mm. runsas A?-peptidin keräytymä
aivoissa että perinnöllistä AT:a aiheuttava mutaatio hermoston kantasoluissa vaikuttavat
niiden elinkykyyn, liikkumiseen ja erilaistumiseen. Tärkeä havainto oli myös se, että
siirretyt kantasolut pystyivät stimuloimaan hiiren omaa hippokampuksen neurogeneesiä
jopa vanhoilla AT-hiirillä.  Osoitimme myös, että Nrf2 suojaa erilaistuvaa hermoston
kantasolua A?-peptidin toksisilta vaikutuksilta ja Nrf2:lla on myös toinen tärkeä
fysiologinen rooli, neurogeneesin säätely.
Luokitus: WL 102, QV 126
Yleinen suomalainen asiasanasto (YSA): hermosto; kantasolut; erilaistuminen; hermosolut; välittäjäaineet;
fragiili X oireyhtymä; Alzheimerin tauti; neurobiologia
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1 Introduction
Currently there are no effective cures for neurodegenerative diseases. The hope to
develop a completely new therapeutic approach for these severe diseases was
realized in 1992 when Reynolds and Weiss isolated a cell population in the adult
brain with stem cell characteristics. These cells were defined as multipotent neural
stem/progenitor cells (NPCs), which have the capacity to differentiate into all
neuronal cell types and glia, both in vitro and in vivo. In the adult brain, NPCs locate
in two restricted regions the dentate gyrus (DG) in hippocampus (subgranular zone,
SGZ), and in the wall of the lateral ventricle (subventricular zone, SVZ) where they
continuously produce new neurons throughout life (Gage 2002). Adult neurogenesis
is speculated to be important in learning and memory, however, the exact role is still
unresolved as well as how it is regulated. Various growth factors, hormones and
neurotransmitters are thought to be the main regulators in adult neurogenesis (Hagg
2005; Pathania et al 2010). In addition, pathological stages and aging have an impact
on neurogenesis.  For example, in Alzheimer´s disease (AD) and in Fragile X
syndrome (FXS), endogenous neurogenesis and neuroplasticity are impaired and
poorly functioning endogenous neurogenesis may contribute to learning and
memory impairment (Taniuchi et al., 2007; Lazarov et al., 2011).
   Cultured human and mouse NPCs provide a unique cell source to study the neural
mechanisms of pathogenesis of various human neurological disorders such as FXS.
The loss of neurons is characteristic to disorders such as AD and Parkinson´s disease
(PD). NPCs can be potentially used for therapeutic purposes in neurodegenerative
diseases in several ways. A brain´s own neurogenesis has limited recovery capacity
and is unable to compensate for neuronal damages completely. The recovering
capacity can be potentially enhanced in two alternative ways: by transplantation of
exogenous NPCs directly into the damaged brain area, or by stimulation of the
patient’s own NPCs pharmacologically to proliferate, differentiate, and replace or
recover damaged neurons.
   The source of NPCs for cell transplantation is still under discussion. NPCs can be
isolated directly from fetal tissue, differentiated from embryonic stem cells (ES), or
reprogrammed from somatic tissue as pluripotent stem cells (iPS). Taking into
account the advantages and disadvantages, the most promising alternative is iPS-
derived NPCs because their availability is unrestricted, and when derived from the
patient´s own cells, NPCs do not cause rejection. However, iPS-derived NPCs
obtained from patients carrying a mutation are genetically similar to all of the
patient’s cells. In some cases, the mutation may have an effect on the function of
transplanted cells and thus reduce the effectiveness of stem cell therapy.
   Another  possibility  is  to  stimulate  a  patient´s  own  neurogenesis.  In  several
diseases, such as AD, the levels of growth factors may be altered which may also
alter endogenous neurogenesis and their recovering capacity. Restoring the levels of
2growth factors by using environmental enrichment (e.g. de novo synthesis or delivery
of growth factors) at the site of disease may have neuroprotective effects. As an
example, delivery of brain derived growth factor (BDNF) into the brain has been
shown to be beneficial in animal models of AD (Blurton-Jones et al., 2009).
   Before the cell replacement therapy of the neurodegenerative disease can be
successfully  applied  in  clinics,  the  mechanisms  of  NPC  survival,  migration,  and
differentiation need to be well understood. It is also equally important to clarify how
the pathology of the disease being treated may affect the transplanted cell survival,
migration, and differentiation. The main characteristics of AD brain are
accumulation of neurotoxic A? plaques and tau aggregations, neuroinflammation
and reactive oxygen species (ROS). These may have impact on delivered as well as
endogenous NPCs.
   NPCs and their differentiation form the link between all of the four studies
presented in this thesis. We chose several approaches to study NPC differentiation in
vitro and in vivo. In addition, we utilized genetic mouse models to study NPC
differentiation and neurogenesis in neurodegenerative diseases. Here, we show that
several neurotransmitters are involved in the early stages of neuronal maturation.
We also used FXS and AD mouse models with typical genetic mutations causing
these disorders. Moreover, we investigated how fragile X mental retardation protein
(FMRP)  deficiency  in  FXS  affects  the  differentiation  of  both  human  and  mouse
NPCs. Next, we provide information about the effects of both AD-linked genotype
as  well  as  AD-mimicking  environment  on  survival,  proliferation,  migration,  and
differentiation of transplanted NPCs. Finally, we investigated the ways to alleviate
AD pathology by studying NPCs and the transcription factor Nrf2. We show that
together with the neuroprotective effects, Nrf2 also has an important function to
promote endogenous neurogenesis.
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2.1 ADULT NEURAL STEM/PROGENITOR CELLS (NPC)
2.1.1 Adult neurogenesis
Adult neurogenesis is a process which includes proliferation, differentiation,
migration, and synaptic integration of newly produced neurons.  It was traditionally
thought  that  neurogenesis  occurs  only  during  embyonic  and  perinatal  stages  of
mammalian development. In the 1960s, a new method of 3H-thymidine
autoradiography to detect cells undergoing DNA synthesis in preparation for
mitosis was generated. This marker for proliferating cells was immediately utilized
by Altman (1962, 1963, 1966, 1969) and Altman and Das (1965, 1966, 1967) who were
the first to report new neurons in the adult rat and cat brain. Fifteen years later, these
findings were confirmed by Kaplan´s ultrastructural studies (Kaplan and Hinds,
1977; Kaplan, 1981; Kaplan and Bell, 1983, 1984). Even thought further evidence for
proliferating  neurons,  and  thus  for  the  existence  of  NPCs  in  the  dentatus  gyrus  of
adult mammalian brain, came from studies by Stanfield and Trice (1988) and
Gue´neau et al., (1982), the pioneering work of these investigators encountered
considerable skepticism and was not taken seriously in the field. It was not earlier
than in the 1990s when neurogenesis in the adult rodent was finally established.
   In 1992, Reynolds and Weiss isolated proliferating cells with stem cell
characteristics in the adult brain and the old dogma of “no new nerve cells formed
after  birth”  could  be  forgotten.  The  finding  of  NPCs  and  the  idea  that  they
theoretically are able to produce new nerve cells and perhaps aid in recovery of
brain damage, provided an opportunity to explore an entirely new research field. In
addition, culture and differentiation of these cells opened a new field for in vitro
studies to study the mechanisms of neurogenesis and their unique potential for
future therapy in neurological disorders.
   In the adult mammalian brain, there are two spatially restricted neurogenic
regions: subventricular zone (SVZ) in the wall of lateral ventricle; and subgranular
zone (SGZ) of the dentate gyrus (DG) in the hippocampus. At these two sites of the
brain, NPCs proliferate and produce new neurons throughout life (Alvarez-Buylla
and Lim, 2004; Lie et al., 2004). Restricted populations of NPCs are also found in
other  brain  areas  such  as  in  the  striatum,  cortex,  optic  nerve,  septum,  corpus
callosum, spinal cord, retina, hypothalamus, and caudal portions of SVZ, (Palmer et
al., 1995, 1999; Weiss et al., 1996; Shihabuddin et al., 1997; Lie et al., 2002).
   NPCs are  classified as  being multipotent  stem cells  meaning that  they are  highly
undifferentiated cells. They have self-renewal capacity and they may generate all
neural  cell  types:  neurons,  astrocytes,  and  oligodendrocytes  in  their  own
environment (Gage 2002; Galli et al., 2003; Bull and Bartlett 2005; Kornblum 2007).
Compared to pluripotent stem cells, which are able to differentiate into all cell types
of the body, the differentiation potential of multipotent cells is more restricted
4(Kazanis 2011). The population of NPCs includes not only multipotent stem cells but
also  bipotent  cells,  which  are  called  progenitor  cells.  Progenitor  cells  show  a  more
restricted proliferation and self-renewal capacity compared to multipotent cells.
Because it is impossible to distinguish multipotent and bipotent cells, they are
together known as NPCs (Bull and Bartlett 2005).
2.1.2 Neurogenic regions
The subventricular zone (SVZ) located along the lateral wall of the lateral ventricles
shows the highest neurogenic rate in the adult brain. In the rat brain, as many as
30 000 new neuroblasts can be produced each day (Alvarez-Byulla et al., 2000). New
SVZ neuroblasts migrate along the rostral migratory stream at their final destination
into the olfactory bulb (OB) and differentiate into local periglomerular inter neurons
(Lois and Alvarez-Buylla 1994; Belluzzi et al., 2003). The subgranular zone (SGZ) in
the hippocampal dentate gyrus (DG) is the second most active neurogenic area and
generates about 9 000 neuroblasts per day. In contrast to olfactory bulb,
hippocampal neuroblasts in SGZ migrate only a short distance into the inner granule
cell layer and differentiate to neurons (Cameron and McKay, 2001).
   A  more  detailed  analysis  of  SVZ  neurogenesis  showed  that  one  SVZ  NPC
population consists of relatively quiescent NPCs. These quiescent cells give rise to
actively proliferating cells, which are also called transit amplifying progenitors
(Doetsch et al., 1996), which then give rise to immature neuroblasts. Neuroblasts
migrate along the rostral migratory stream into the OB and differentiate into
interneurons, especially granule and periglomerular cells (Lois and Alvarez-Buylla
1994; Belluzzi et al., 2003). SVZ progenitors express Nestin and Sox2 and
interestingly, despite their stem cell characteristics, also express glial fibrillary acidic
protein (GFAP) and glial glutamate transporter (GLAST). Both of these markers are
typically associated with differentiated astrocytes (Doetsch et al., 1997; Colak et al.,
2008; Kriegstein and Alvarez-Buylla 2009). In vitro, proliferating NPCs have
neurosphere-forming ability. Neurospheres are freely floating cell clusters (Doetsch
et al., 2002).
   Analysis of SGZ NPCs has demonstrated that there are early precursor cells which
have morphological and antigenic features similar to radial glia. Similar to the SVZ,
there is an abundant population of slowly proliferating progenitors also in the SGZ
which  express  GFAP,  Sox2,  and  Nestin.  Slowly  proliferating  progenitors  then  give
rise to fast proliferating precursor nonradial cells, which still express Sox2 and
Nestin, but not GFAP. These cells give rise to neuroblasts, which express
doublecortin (DCX) and differentiate into glutamatergic dentate granule cells (Seki
and Arai 1993; Fukuda et al., 2003; Seri et al., 2004; Mu and Gage 2012). Later, more
mature neurons express neuronal specific nuclear protein (NeuN) (Figure 1).
5Figure 1. (A)  Adult  NPCs  are  found  in  the  SVZ and  SGZ of  the  mammalian  brain.  (B)
Shematic representation of the dentate gyrus SGZ which is the other main region in the
adult mammalian brain where new neurons are generated continuously throughout life
(modified from Ma et al., 2009a and Ming and Song, 2005).
   Taken together,  in  both adult  neurogenic  regions,  SVZ and SGZ NPCs show first
astroglial morphology, then generate precursors of neuronal commitment
(neuroblasts), which are able to migrate to their targets, differentiate to mature
neurons, and finally integrate into the neural network. Despite the fact that
thousands of new neurons are generated per day, only a small proportion of these
survive and finally integrate into neural circuits (Kemperman et al., 2004; Ma et al.,
2009a,b, Cameron 2001). Dead and dying neurons are removed by phagocytosis glial
cells which play the major phagocytic role in the central nervous system. In addition,
DCX positive NPCs have been shown to play an unexpected phagocytic role, but
this may occur in only specific neurogenic areas (Lu et al., 2011).
2.1.3 Regulation of adult neurogenesis
Postnatal neurogenesis is a dynamic process modulated by various genetic,
environmental and pharmacological factors. The specific neurogenic area, where
NPCs are laying is also called a “niche”, which plays a dominant role in the
regulation of NPCs. The niche comprises various cell types including endothelial
cells, astrocytes, ependymal cells, microglia, mature neurons, and vascular cells
which all have their own roles in the regulation of proliferation, migration, fate
specification, maturation, or synapse formation of NPCs (Palmer et al., 2000; Shen et
al., 2008; Tavazoie et al., 2008; Kojima et al., 2010; Morrens et al., 2012; Barkho et al.,
2006; Lim et al., 2006; Ekdahl et al., 2003; Sierra et al., 2010).
   Many factors are known to clearly influence the rate of neurogenesis. However, the
exact mechanism of how adult neurogenesis is regulated is not completely
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6elucidated. Regulators could be categorized into intracellular and extracellular
players. Intracellular players are for example cell-cycle regulators, transcription
factors, genetic, and epigenetic factors (Zhao et al., 2008). The main extracellular
players are cytokines, hormones and growth factors including neurotrophins
(Pathania et al., 2010; Zhao et al., 2008). Several classical neurotransmitters have also
been reported to directly or undirectly regulate NPCs (Sahay and Hen, 2007;
Warner-Schmidt and Duman, 2006).
   Other important factors which are known to affect the rate of neurogenesis are for
example environmental enrichment and exercise, which increases neurogenesis
(Kemperman et al., 1997; van Praag et al., 1999), whereas aging (Bizon and Gallagher
2005), stress (Lemaire et al., 2000), oxidative stress (Yoneyama et al., 2011), and a
number of toxins and drugs (Eisch and Harburg 2006; Nixon and Crews 2002) have
shown the opposite effects. Many neurological diseases associate with alterations in
neurogenesis (Grote and Hannan 2007). Neuronal injury and ischemia have been
shown to stimulate NPCs to become active and migrate towards the lesioned area
(Yoneyama et al., 2011; Arvidsson et al., 2002; Nakatomi et al., 2002) and
neurological diseases including AD and FXS have been associated with either
impaired or increased neurogenesis (Choi et al., 2008; Luo et al., 2010; Lazarov et al.,
2011; Taniuchi et al., 2007; Jin et al., 2004).
   There is a body of evidence that new neurons are generated in the adult brain and
the  rate  of  neurogenesis  is  highly  sensitive  to  various  physiological  and
environmental stimuli. However, the exact role of adult neurogenesis has not been
fully elucidated and is still under intensive investigation. Several studies suggest
that newly produced neurons in the hippocampus may play an important role in
learning and memory (Imayoshi et al. 2008; Kemperman and Gage 2002; Lledo et al.,
2006; Deng et al., 2009; Gould et al., 1999; Tronel et al., 2010). It has been shown that
boosting adult neurogenesis facilitates pattern separation and memory when
investigated using Morris water maze analyses (Sahay et al., 2011; Stone et al., 2011).
In addition, decreased neurogenesis results in cognitive impairment which is typical
in aging and particularly in AD patients (Clelland et al., 2009; Lazarov et al., 2010).
The role of the SVZ neurogenesis is less clear compared to hippocampal
neurogenesis. Previous studies suggest that SVZ neurogenesis is involved in
synaptic plasticity and function in olfaction (Nissant et al., 2009; Doetsch and Hen
2005). Recently, it has been also shown that both SGZ and SVZ neurogenesis are
involved in offspring recognition (Mak and Weiss 2010).
2.1.4 Cultivation of NPCs in vitro and therapeutic possibilities
After Reynolds and Weiss (1992) demonstrated the methods to isolate cultured
NPCs, NPCs have been routinely used in in vitro experiments. NPCs can be kept in
an undifferentiated stage by adding growth factors: epidermal growth factor (EGF)
and basic fibroblastic growth factor (bFGF). In the presence of growth factors in
serum-free media, NPCs proliferate and form freely floating cell aggregates called
´neurospheres´. Expanded neurospheres are dissociated to single cells which form
7secondary neurospheres in culture. This procedure can be repeated several times to
obtain an exponentially growing cell population (Galli et al., 2003). Actually, single
neurospheres are not homogenous populations of neural stem cells. A neurosphere
contains only 10-50% of cells with real stem cell characteristics; the rest of the cells
are differentiating progenitor cells and even more mature cells (Galli et al., 2008).
Removal of mitogens from the culture media causes spontaneous differentiation of
NPCs and the cells differentiate into neurons, astrocytes, and oligodendrocytes.
   Cultured human or mouse NPCs offers excellent tools to study and understand the
mechanisms of normal neurogenesis as well as its disturbances in various
neurological diseases. Especially, NPCs offer valuable tools for studying the
mechanisms underlying neurogenesis in disorders, which are caused by single-gene
defects such as FMRP mutation in FXS. By using genetically modified mouse models
or human NPCs generated from affected aborted fetuses, it is possible to study how
genetic as well as environmental factors affect the behavior of NPCs (Bhattacharyya
et al., 2008a). NPCs can also be useful for drug screening, when testing the drugs
which have effects on developing neurons (Ma et al., 2009b). In addition, NPC
technologies and stem cell therapy have become a potential option to treat several
neurodegenerative disorders. Because a typical feature of several neurodegenerative
disorders  such  as  PD,  AD,  spinal  cord  injury,  and  stroke  is  the  irreversible  loss  of
neurons in the CNS (Lindvall and Kokaia 2006), a possible treatment could be stem
cell transplantation. Transplanted in vitro-expanded  NPCs  are  either  expected  to
directly replace damaged or lost neurons or they may have trophic function which
support the neurons at risk to die or even stimulate endogenous NPCs (Park et al.,
2010). Several experiments carried out in animal models have given promising
results, which encourage the tests of stem cell therapy also in humans (Lindvall and
Kokaia 2006; Shetty and Hattiangady 2007; Einstein and Ben-Hur 2008; Blurton-Jones
et al., 2009; Yamasaki et al., 2007).
   The best NPC source for stem cell therapy is still under discussion. Human NPCs
can be isolated from aborted fetuses, derived from pluripotent embryonic stem cells
(ES), or induced pluripotent stem cells (iPS). ES cells are isolated from the inner cell
mass of a developing blastocyst. ES cells are pluripotent and may have the capacity
to give rise to cells from all three germ layers. Pluripotent stem cells are also able to
form teratomas. After differentiation into more restricted NPCs they lose the ability
to form teratomas. Multipotent NPCs could also be isolated from aborted fetuses
directly. In both alternatives, ES-derived NPCs or NPCs isolated from aborted
fetuses, are associated with ethical problems and cause host-versus-donor rejections,
when the  transplanted cells  from outside  sources  cause  immunereactions  and cells
will die (Bithell and Williams 2005). In addition, because the availability of aborted
features and developing human blastocysts is limited, the amount of ES- and fetus-
derived NPCs is restricted. Thus, a feasible cell source for cell therapies is NPCs
derived from the patient´s own tissue. Therefore, the best option for a stem cell
source probably are the iPS-derived NPCs. iPS cells are first generated from a
patient’s own somatic cells by reprogramming them back to the pluripotent stage
8(Takahashi and Yamanaka 2006; Takahashi et al., 2007). These iPS cells showed
similar ability to form teratomas as ES. When the iPS cells are differentiated to NPCs
and thereafter to neural cells they lose the ability to form teratomas (Wernig et al.,
2008). Compared to ES cells, because the starting material is the patient’s own
mature  cells,  it  is  possible  to  avoid  the  rejection  problems  and  the  usage  of
immunosuppressive drugs. The use of the patient’s own somatic cells also excludes
ethical concerns. However, problems can occur in patients with genetic disease if the
mutations which cause the disease also have negative effects on functions of NPCs
(Choi et al., 2008).
   It is known that many pathological conditions such as ischemia and stroke increase
endogenous neurogenesis which is, however, not sufficient to fully compensate for
all neuronal damage (Kokaia and Lindvall 2003). This observation raises the notion
that it could be possible to activate a patient’s own neurogenesis and cell
mobilization during or after the pathological stages (Ma et al., 2009b; Gage 2004).
Even  though  the  number  of  newly  produced  neurons  probably  is  relatively  small,
compared to dead and damaged neuronal cells, the stimulation may still enhance the
regenerative and recovery processes during the disease (Mu and Gage 2011). One
important group of molecules, which regulates neurogenesis are growth factors. The
levels of growth factors have been shown to be altered in several pathological states.
For example in AD brain, the decreased levels of BDNF may contribute to the
progression of the disease (Blurton-Jones et al., 2009). In previous studies, enhanced
levels of bFGF, BDNF, and vascular endothelial growth factor (VEGF) have been
shown to stimulate NPCs and thereby they may alleviate the symptoms of diseases
in animal models (Nakatomi et al., 2002; Kim et al., 2009; Blurton-Jones et al., 2009).
Other  factors  that  could  be  useful  for  stimulation  of  patient  own  neurogenesis  are
cytokines, certain drugs, and even enhanced physical activity (Mu and Gage 2011).
   The stimulation of a patient’s own NPCs offers many advantages when compared
to  cell  transplantation.  By  stimulating  endogenous  neurogenesis  it  is  possible  to
avoid rejection complications, location-specific recruitment is better achieved and
generated progenitors possibly maturate and integrate better than exogenously
transplanted NPCs (Ma et al., 2009b). However, the mechanisms which regulate
NPCs and modulate endogenous neurogenesis should be fully characterized before
any clinical application. Despite intensive studies, the mechanisms which regulate
NPCs are still poorly understood. Furthermore, it is also equally important to
understand how the diseased brain environment and genetic mutations affect the
behavior of NPCs.
2.1.5 Neurotransmitters in the regulation of NPCs
The classical role of neurotransmitters is to mediate chemical communication
between neurons. In addition, neurotransmitters play an important role in cell
development during the embryonic stage (Nquyen et al., 2001; Emerit et al., 1992)
and may also have a role in the regulation of adult neurogenesis (Gould et al., 1994;
Cameron et al., 1995; Hagg et al., 2009). Neurotransmitters could even be master
9regulators, that control various stages of neurogenesis (Platel et al., 2010b). However,
the importance of neurotransmitters in the regulation of NPCs is largely unknown
and further investigation is needed. Neurotransmitters are speculated to affect
differently various NPC subpopulations and stages of neurogenesis (Merkle et al.,
2007). They are also speculated to have an indirect role on NPCs. For example, the
usage of a serotonin reuptake inhibitor increases BDNF, which further increases
neurogenesis (Duan et al., 2008).
   Activation of several neurotransmitter receptors stimulates the elevation of
intracellular calcium (Ca2+) levels, which then triggers plastic changes in neurons
(Spitzer et al., 2004; Deisseroth et al., 2004). Ca2+ ion is a universal intracellular
messenger that controls a wide range of cellular functions such as gene transcription,
neurotransmitter release, vesicular secretion, activation of enzymes, apoptosis,
fertilization,  and  many  more.  Even  though  Ca2+ is a very common intracellular
messenger,  it  also  mediates  very  specific  functions.  Specificity  is  possible  by  using
different entry, exit, and distribution routes inside cells. Intracellular Ca2+ elevation is
mediated either by transporting extracellular Ca2+ via ionotropic receptors inside the
cell or via G protein-coupled receptors (GPCR) which then activate intracellular Ca2+
release from intracellular stores (Clapham 1995; 2007; Berridge et al., 2003).
Ionotropic receptors
Ca2+ enters cells by passing through specific Ca2+ channels. The movement between
inside and outside the cell is dependent on the electrochemical gradient. In excitable
cells, voltage-operated Ca2+ -channels (VOCs) generate the fast Ca2+ fluxes which
then control fast cellular processes. This group of channels includes also channels
which respond to external stimuli. They are called receptor-operated Ca2+ -channels
(ROCs). For example the N-methyl-D-aspartate (NMDA) receptor responds to
external glutamate, opening the Ca2+ channel,  allowing Ca2+ to  flow inside the  cell,
and then link to other signaling components.
   Other channels are second-messenger-operated channels (SMOCs) that are
controlled by internal messengers and store-operated channels (SOCs) which open
in response to depletion of internal Ca2+ stores. Many of these channels are classified
into the large transient receptor protein (TRP) ion-channel family, which are known
to  be  involved  in  important  slow  cellular  processes  such  as  cell  proliferation
(Berridge et al., 2003).
G protein coupled receptors (GPCR)
GPCRs are a large membrane protein superfamily, which mediate a wide variety of
cellular responses, including the responses of various neurotransmitters. Most
neurotransmitters have been shown to activate G protein coupled metabotropic
receptors and, in contrast to ionotropic receptors, mediate slow responses
(Wettschureck and Offermanns 2005). GPCRs form a seven transmembrane ?-helical
bundle  which  has  three  intra-  and  extracellular  loop  regions.  GPCRs  are   divided
into six protein families based on their structure and sequence similarities:
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rhodopsin receptors (A), secretin receptors (B), glutamate receptors (C), fungus
pheromone receptors  (D), cAMP receptors (E), and  frizzled/smoothened receptors
(F) (Rosenbaum et al., 2009; Tuteja 2009). Biological effects occur when
neurotransmitters bind to the GPCR, recruit heterotrimeric G proteins (GTP-binding
protein), and activate GTP-GDP exchange. This exchange results in the dissociation
of the GTP-bound ?-subunit and ??-subunit from the GPCR (Karnik et al., 2003).
Both G?-subunit and G??-subunit can independently mediate several signaling
pathways such as activation of phospholipases, modulation of adenylate cyclases,
and gating of ion channels (Gether 2000). G? proteins  are  also  divided  into  four
families: Gq/G11,  Gi/Go, Gs, and G12/G13 proteins. In the nervous system, Gq/G11 are
widely expressed and modulate neuronal fuctions (Wettschureck and Offermanns
2005). Activation of the specific neurotransmitter receptor activates usually Gq/G11
protein,  which  then  couples  to  phosholipase  C  (PLC)  and  leads  to  hydrolysis  of
phosphatidyl-inositol-bis-phosphate (PIP2). After hydrolytic cleavage, PIP2 generates
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which then activates
protein  kinase  C  (PKC).  IP3 mediates Ca2+ mobilization from intracellular stores,
which finally promotes several Ca2+-dependent processes such as activation of
enzymes, secretion, or gene transcription. Inside the neuronal cells, the main
intracellular Ca2+ stores are in endoplasmic reticulum (ER). After Ca2+ release it is
pumped back into the ER via sarcoplasmic-reticulum-associated Ca2+ ATPase
(Berridge et al. 2000; Berridge et al., 2004).
Neurotransmitters
Neurotransmitters are classified as classical neurotransmitters such as ?-amino
butyric acid (GABA) and glutamate (Glu), and as neuromodulators such as
dopamine, serotonin and acetylcholine (ACh) (Young et al., 2011). In previous
studies, at least dopamine, serotonin, GABA, ACh, noradrenaline (NE), and
glutamate have been shown to have effects on different stages of NPC
differentiation. However, the regulation of SVZ neurogenesis by neurotransmitters
is better understood than the role of neurotransmitters in SGZ neurogenesis.
   Both dopamine and serotonin are known to regulate mood, motivation, and
movement. In addition, both have effects on SVZ neurogenesis. Dopaminergic
afferents have been found to be in direct contact with transit amplifying cells in SVZ
(Hoglinger et al., 2004) and cultured SVZ neurospheres have been demonstrated to
express dopamine receptors (Coronas et al., 2004; Hoglinger et al., 2004; Winner et
al., 2009). In mouse models of PD, when dopaminergic inputs are prevented, also
proliferation and differentiation of SVZ NPCs have been shown to be decreased
(Borta and Hoglinger 2007; O´Keeffe et al., 2009a,b; Cova et al., 2010; Freudlieb et al.,
2006; Baker et al., 2004). Furthermore, increased SVZ neurogenesis has been
observed by administration of a dopaminergic agonist (Yang et al., 2008). Serotonin
regulates positively both SGZ and SVZ NPC proliferation and neurogenesis
throughout several serotonergic receptor subtypes (Banasr et al., 2004; Brezun and
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Daszuta 1999). In addition, direct in vivo infusion of serotonin increases proliferation
and neurosphere formation of cultured SVZ NPCs (Hitoshi et al., 2007).
   GABA is the main inhibitory neurotransmitter in adult brain. Functional GABA
receptors are identified also on astrocytes and neuroblasts from SVZ (Stewart et al.,
2002; Nguyen et al., 2003; Gascon et al., 2006). Striatum, which is located adjacent to
the  SVZ,  is  mainly  composed  of  GABAergic  neurons,  therefore  it  is  not  surprising
that  GABA  has  a  negative  effect  on  proliferation  and  differentiation  of  SVZ  NPCs
(Nguyen et al., 2003; Liu et al., 2005).
   One important neurotransmitter, glutamate, acts either via ionotropic receptors
AMPA, kainate, and NMDA (Hollman and Heinemann 1994), or via group I-III
metabotropic receptors 1-8 (mGluR1-8) (Goutinho and Knopfel 2002). Both
ionotropic and metabotropic receptor types were identified in SVZ NPCs (Brazel et
al., 2005; Young et al., 2011). Neuroblasts express AMPA, kainate, NMDA and
mGluR5 receptors (Platel et al., 2007; Platel et al., 2008b; Platel et al., 2010a) and
interestingly, during the migration along rostral migratory stream, the number of
NMDA receptors in neuroblasts is increased (Platel et al., 2010a). The expression of
various types of glutamate receptors in NPCs indicates that these receptors mediate
also various cellular functions. Glutamate has already been shown to affect
proliferation, migration, and cell survival. Inhibition of kainate receptors stimulated
the migration of neuroblasts (Platel et al., 2008a, b). Mice without functioning
mGluR5 or mice with mGluR5 antagonist showed a reduced number of proliferating
cells in SVZ (Di Giorgi-Gerevini et al., 2004, 2005). Moreover, mice without
functional NMDA receptors resulted in increased apoptosis of migrating neuroblasts
which eventually led to reduced neurogenesis in olfactory bulb (Platel et al., 2010a;
Lin et al., 2010).
   Finally, important neurotransmitters which have been shown to affect NPCs are
ACh and NE. ACh signals are mediated via ionotropic nicotinic or metabotropic
muscarinic ACh receptors. Even though the number of cholinergic afferents is
relatively small, they are widespread in the brain (Young et al., 2011). There are
several studies which show that the cholinergic system and ACh are involved in the
regulation of adult hippocampal neurogenesis, especially proliferation of NPCs.
Cholinergic stimulation increased proliferation of hippocampal NPCs (Itou et al.,
2011). Lesions in medial septum systems have been shown to decrease the
proliferation of NPCs (Cooper-Kuhn et al., 2004; Mohapel et al., 2005; Van der
Borght et al., 2005). Increased ACh obtained via use of a acetylcholine esterase
inhibitor also increased proliferation of NPCs (Mohapel et al., 2005; Narimatsu et al.,
2009). Also, in vitro stimulation  of  muscarinic  ACh  receptor  was  found  to  be
involved in proliferation and differentiation of NPCs (Zhou et al., 2004). Recently,
NE has been shown to affect the proliferation of SGZ NPCs (Jhaveri et al., 2010;
Masuda et al., 2011).
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2.2 FRAGILE X SYNDROME (FXS)
2.2.1 Clinical features and neuropathology of FXS
Fragile X syndrome (FXS) is a common X-linked inherited form of human mental
disability; one in every 4000 males and one in every 8000 females suffer from this
syndrome (Huber et al., 2002). FXS was first documented in 1943 as a familiar form
of X chromosome-linked cognitive impairment. The disease was called Martin-Bell
syndrome until 1991 when the Fragile X Mental Retardation 1 (FMR1) gene was
found and the disease was renamed FXS (Fu et al., 1991; Verkerk et al., 1991).
   The severity and symptoms of the disease vary widely between the FXS
individuals and also between the genders. Even though both males and females can
be affected, the symptoms and phenotypes are typically more severe in males.  The
severity  of  dysfunctions  in  females  is  dependent  to  the  degree  of  X-inactivation on
the abnormal  chromosome (Willemsen et  al.,  2011).    Typical  characteristics  of  FXS
males are recognizable long face, large ears, hyperextensible joints, and enlarged
testicles. Delayed speech and language development often leads to the diagnosis and
the phenotype includes mild to severe intellectual disability, autistic behavior,
hyperactivity, attention deficits, social anxiety, sensory-processing problems, and
epilepsy. Postmortem analysis of FXS brains has revealed morphological changes in
dendritic spines (Bear et al., 2004; Wilson and Cox 2007).
   Dendritic spines are small membranous protrusions from dendrites of neurons,
which receive input from the synapse of an axon. They act as storage sites, support
the electrical signal transmission, increase the surface area of dendrites, and thereby
increase the number of possible contacts with other nerve cells (Yuste 2011). Dedritic
spines  also  have  been  shown  to  express  GluRs  (e.g. AMPA  and  NMDA  receptors)
which mediate a wide variety of signals. Cognitive function, motivation, learning,
memory, and long-term potentiation (LTP) are especially dependent on spine
plasticity.  During normal  neurogenesis  dendritic  spines  mature  or  they are  pruned
(eliminated). If the maturation or pruning of spines is disturbed, spines show
immature morphological features (e.g. long “necks” or  lack of  “head”),  which then
may also alter signal transduction (Chonchaiya et al., 2009). Correct regulation of the
morphology of dedritic spines is important and the morphological abnormalities are
widely associated with mental retardation (von Bohlen and Halbach, 2010).
   Dendrities in many brain regions of FXS individuals have morphologically longer,
thinner, and otherwise immature spines. These morphological changes were long
thought to indicate defective spine pruning (Bear et al., 2004; Wilson and Cox 2007).
Recently, it was shown that both formation and elimination of spines (so called spine
turnover)  is  increased  in  a  mouse  model  of  FXS  (Fmr1 KO  mice)  compared  to  wt
mice. In addition, Fmr1 KO  mice  have  a  higher  amount  of  instable,   so  called
transient spines, with smaller head diameter and longer neck compared to stable
spines.  A  high  number  of  transient  spines  of Fmr1 KO  mice  may  contribute  to  the
immature spine phenotype in Fmr1 KO mice (Pan et al., 2010).
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   Numerous  studies  have  shown  that  FXS  is  a  monogenic  disorder  and  the  loss  of
function of the FMR1 gene  underlies  the  pathogenesis  of  FXS.  Over  95  %  of  FXS
cases are caused by the CGG trinucleotide repeat mutation (O´Donnell and Warren,
2002). CGG repeats are observed in the 5´untranslated region of the FMR1 gene. The
length of the CGG trinucleotide repeat varies even within a normal population.
During maternal transmission, CGG repeats may become unstable resulting in the
expansion of the repeat in the next generation. In unaffected individuals, the CGG
region contains 5 – 50 repeats, whereas premutation carriers have 50 – 200 CGG
repeats. In a full mutation of FXS individuals, CGG repeats are massively increased
and show over 200 repeats. The full mutation leads to methylation of CGG repeats
and FMR1 promoter which then silences the FMR1 gene and causes the loss of gene
expression and finally loss of FMRP results in the phenotype of FXS (Ashley et al.,
1993; Verkerk et al., 1991; Pfeiffer and Huber 2009; Santoro et al. 2011; Willemsen et
al., 2011).
   In premutation carriers, the level of FMR1 mRNA has been shown to be increased;
but surprisingly, the levels of FMRP have been reported to be decreased (Tassone et
al., 2007). Having intermediate numbers of CGG repeats does not result in FXS, but
may cause two other disorders. Premutation carrying females have a risk for fragile
X-related primary ovarian insufficiency which leads to ovarian failure during the
teenage years and approximately 5 years earlier menopause. Ovarian dysfunction
depends on repeat size, but the molecular mechanisms behind this disease are still
largely unknown (Allingham-Hawkins et al., 1999; Murray 2000; Willemsen et al.,
2011). Still another disease reported in premutation carriers is fragile X-associated
tremor/ataxia syndrome, which is a late-onset neurodegenerative disorder. The
symptoms of this disease vary greatly between premutation carriers. Characteristics
of this disease together with tremor and ataxia are progressive cognitive decline
(Jacquemont et al., 2004).
   To  study  the  molecular  mechanisms  causing  FXS,  a Fmr1 knockout (KO) mouse
model is widely used. These mice completely lack the expression of FMRP and they
show similar morphological abnormalities in synapse structures and altered synapse
function as FXS individuals (Comery et al., 1997; Braun and Segal 2000; Irwin et al.,
2000; Nimichinsky et al., 2001; Galvez et al., 2003). In addition, Fmr1 KO mice show
deficits in spatial learning, hyperactive behavior, and audiogenic epilepsy (Bakker et
al. 1994; Kooy et al. 1996; Paradee et al. 1999; Dobkin et al. 2000; Chen and Toth 2001;
Nielsen et al. 2002; Frankland et al. 2004; Qin et al. 2005; Spencer et al. 2011).
2.2.2 Fragile X mental retardation protein (FMRP)
FMRP belongs to a family of RNA binding proteins, nuclear ribonucleoproteins,
which have strong affinity to RNA (Van de Bor and Davis 2004).  FMRP contains
three RNA-binding motifs: two K homology domains and an arginine-glycine-
glycine  box  which  binds  to  RNA  in  a  sequence-specific  manner  via  these  domains
(Blackwell et al., 2010; Ashley et al., 1993). However, other types of interactions act
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through  adaptive  brain  cytoplasmic  1  protein,  which  first  binds  to  the  FMRP  and
then interacts with the FMRP targets (Zalfa et al., 2003; Zalfa et al., 2005).
   FMRP is ubiquitously expressed both in fetal and adult tissues, most abundantly in
the brain and testes (Devys et al., 1993). In the brain, the highest FMRP expression is
detected in neurons, where it is found in the neuronal cell body as well as in
dendrites and spines. FMRP is associated with ribosomes both in cytoplasmic and
endoplasmic reticulum (ER) (Antar et al., 2004; Feng et al., 1997; Wilson and Cox
2007). FMRP is also found in the nucleus, indicating that this protein shuttles
between the nucleus and cytoplasm (Devys et al., 1993; Van de Bor and Davis 2004).
In  nucleus,  FMRP  has  been  suggested  to  bind  to  its  own  mRNA  and  thereby
facilitate (chaperone) transportation of mRNA out of the nucleus (Eberhart et al.,
1996). It has been estimated that FMRP interacts with 4 % of brain mRNAs (Brown et
al., 2001). These mRNAs include many mRNAs which are involved in neuronal and
synaptic  transmission  and  they  also  include  several  candidate  genes  for  autism
(Darnell et al., 2011). In the testes, FMRP has a role in testes development and
maintenance of male fecundity. Male FXS patients have been shown to have
enlarged testes and defects of spermatogenesis leading to reduced fecundity (Turner
et al., 1980; Nistal et al., 1992).
   Several studies have shown that FMRP acts as a translational repressor for those
mRNAs, which associate with FMRP (Laggerbauer et al., 2001; Li et al., 2001;
Mazroui et al., 2002). One role of FMRP is to repress the translation of microtubule-
associated protein 1B (MAP1B) (Lu et al., 2004). MAP has an important role in
stabilization of microtubules during the elongation of dendrites, neurites and their
morphological structures (Gonzalez-Billault et al., 2004). Thus, the absence of FMRP
may lead to altered microtubule dynamics which promotes the alterations of spine
morphology (Lu et al., 2004; von Bohlen and Halbach 2010).
   By regulating protein translation at the synaptic site FMRP modulates synaptic
plasticity that is important for learning and memory (Antar and Bassell 2003; Bagni
and Greenough 2005; Bassell and Warren 2008). Synaptic plasticity, defined as the
ability to change synaptic structure, can be divided into two categories: long-term
potentiation (LTP) and long-term depression (LTD). Both of these plasticity forms
include several cellular and molecular mechanisms, which either enhance or weaken
the function of specific synapses. The mGluRs are involved in LTD. In normal brain,
activation  of  group  1  mGluRs  increases  the  synthesis  of  FMRP,  which  then
negatively regulates the protein translation involved in the internalization of
AMPAR (Bagni  and Greenough 2005).  In  the  spines  of  FXS patients  or  similarly  in
FMR1 deficient  mice,  the  absence  of  FMRP  results  in  increased  translation  of  LTD
proteins. LTD proteins are involved in AMPA and NMDA internalization leading to
lower number of receptors on the postsynaptic membrane and plasticity changes
(Bagni and Greenough 2005).
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Figure 2. A  schematic  model  of  FMRP at  wt  synapse  and  synapse  of  a  FXS patient  or
Fmr1 KO mouse. (A) In the normal spine, stimulation of mGluR enhances the synthesis
of  FMRP.  FMRP  negatively  regulates  the  translation  of  proteins  which  are  involved  in
ionotropic receptor internalization (AMPA and NMDA) during LTD and the proteins that
regulate  the  cytoskeleton  (such  as  MAP1B).  (B)  In  the  FXS  spine,  the  lack  of  FMRP-
mediated repression leads to an increase or decrease in the translation of proteins
involved in the regulation of cytoskeletion and in ionotropic receptor internalization
during  LTD  leading  to  reduced  receptor  number  on  the  postsynaptic  site  and  thinner
spines (modified from Bagni and Greenough, 2005).
2.2.3 FMRP deficiency and NPCs
FMRP  is  widely  expressed  throughout  the  brain  during  embryonic  brain
development (Devys et al. 1993; Hinds et al., 1993; Abitbol et al., 1993), especially in
the areas which contain proliferating progenitor cells and newly born neurons (Rife
et al., 2004). Peak levels of FMRP expression have been detected at the end of the
first postnatal week, declining gradually thereafter (Lu et al., 2004; Wang et al.,
2004). These results indicate that FMRP may have an important role during
development. NPCs offer great possibilities to study the mechanisms of early
neuronal development in FXS. Cultured human NPCs propagated from FXS fetuses
or Fmr1 KO  mice  completely  lack  the  synthesis  of  FMRP  and  were  used  to  study
effects of FMRP deficiency on the neurobiology of NPCs (Jakel et al., 2004).
FMRP
AMPA receptor
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mGluR receptor
Ribosomes
regulator of AMPA
internalization
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INT.  AMPA internalization
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However, the way FMRP regulates embryonic development via proliferation,
migration and differentiation of neuronal cells has not been well characterized.
Another important question is whether FMRP has a role also in adult neurogenesis
and how FMRP deficiency affects learning and memory.
   It has been suggested in several studies that adult neurogenesis is critical for
hippocampus-dependent learning (Ming and Song, 2005) and the disturbed
regulation of neurogenesis may lead to learning and memory deficits. Recent studies
have suggested that FMRP plays an important role in adult hippocampus-dependent
learning and neurogenesis and the deficiency of FMRP leads to impaired learning
and reduced hippocampal neurogenesis in Fmr1 KO mice (Guo et al., 2011; Brennan
et al., 2006; Zhao et al., 2005). It has been shown that FMRP regulates several factors
such as CDK4 and cyclin D1, which are cell-cycle regulators, (Miyashiro et al., 2003)
and glycogen synthase kinase 3? (GSK3?). These signaling molecules are involved in
the regulation of proliferation and differentiation of NPCs (Bhattacharyya et al.,
2008a; Callan et al., 2010; Luo et al., 2010; Lazarov et al., 2011). Increased expression
of  both  CDK4  and  cyclin  D1  has  been  shown  to  increase  proliferation  of  NPCs
(Jablonska et al., 2007; Kenney et al., 2000). Therefore, it is not suprising that due to
lack  of  FMRP  negative  regulation,  the  proliferation  of  NPCs  is  increased  in  the
mouse model of FXS (Luo et al., 2010).
   GSK3? is  known to  be  important  for  cellular  signal  transduction;  and it  acts  as  a
negative regulator of both canonical Wnt signaling pathways and ?-catenin (Hur and
Zhou, 2010). Levels of GSK3? have been shown to be increased both in Fmr1-KO
mice and FXS patients (Luo et al., 2010; Min et al., 2009). FMRP is known to
negatively regulate the level of GSK3? and due to lack of FMRP, the levels of GSK3?
are elevated. Elevated GSK3? then inhibits the Wnt signaling pathway, which again
alters neurogenin1 expression. Neurogenin1 is a transcription factor that promotes
neuronal differentiation and inhibits astrocyte differentiation at the early stage of
differentiation (Guo et el., 2011; Luo et al., 2010; Hur and Zhou 2010; Sun et al., 2001).
   Luo and coworkers (2010) recently demonstrated that hippocampal Fmr1-deficient
adult NPCs have a higher proliferation rate, and differentiate more into glial cells
and less into neurons. Recent studies have also shown that inhibition of GSK3?
rescues hippocampal neurogenesis and enhances hippocampus-dependent learning.
Althogether, these results indicate that GSK3? inhibition could be a potential
therapeutic target for FXS (Guo et al., 2012; Min et al., 2009).
2.3 ALZHEIMER´S DISEASE (AD)
2.3.1 General features of AD
AD  is  the  most  common  neurodegenerative  disorder  in  the  elderly.  It  is
multifactorial, heterogenous, and progressive disease, which finally leads to loss of
neurons in specific brain areas. Neuronal loss occurs typically in areas which are
associated with cognitive functions. Clinical characteristics of AD include the
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progressive memory loss, deficits in other cognitive skills, and psychiatric problems.
Pathologically, sporadic (SAD) and familiar (FAD) forms of AD have similar
pathological features including dramatic neuronal and synaptic loss in the
hippocampus and cerebral cortex, appearance of neuritic plaques (amyloid plaques),
neurofibrillary tangles (NFT), and reduced brain size compared to healthy brain.
Inflammation and OS are also characteristic to AD brain (Marques et al., 2010) as
well as microvascular dysfunction and/or degeneration, accompanied with defects in
the function of blood-brain barrier and vascular factors (Zlokovic 2011).
   The most typical pathological hallmarks of AD, extracellular amyloid plaques and
NFT,  were  first  described  in  1907  by  Dr.  Alois  Alzheimer  in  the  brain  of  a  patient
who suffered from dementia. Despite these findings, intensive AD research started
only in the mid 1960s, when the first reports on the deficits of specific
neurotransmitter systems were announced. The first hypothesis was that reduced
production of ACh caused AD. Therefore, the earliest AD therapies were developed
to preserve ACh (Arce et al., 2009). These therapies only relieve the symptoms, but
do not cure the disease, which indicates that AD is a more complex disease. In the
1980s, amyloid plaques were reported to be composed of extracellular deposits of ?-
amyloid and NFT composed of hyperphosphorylated tau protein filaments. Finally,
in the 1990s, the mutations involved in amyloid precursor protein (APP) proteolytic
processing  and  the  fate  of  A? came  into  focus  and  then  the  modern  era  of  AD
research began (Selkoe 2001; Glenner et al., 1984; De Strooper 2010).
   Presently, it is estimated that dementia affects approximately 24 million people
around the world. The majority of these people have typical AD pathology and
dementia, and are thus classified as AD. In addition, the number of people suffering
from AD will be expected to rise, because the life expectancy of people is increased.
In 2020, approximately 42 million people are estimated to suffer from dementia
(Ballard  et  al.,  2011).   Even  though  the  pathology  of  AD  is  under  extensive
investigation, the mechanisms behind this disease are still poorly known. The
complex nature of this disease makes it challenging for drug development.
Therefore, effective treatment for this disease is still lacking. Current treatments for
AD only relieve the symptoms, but do not stop the progression of the disease or cure
neuronal damage. The multifactorial nature of this disease will probably require a
combination of different therapeutic approaches in order to be effective (De Strooper
2010). However, in the near future the development of new therapeutic approaches
would be of utmost importance to avoid the enormous economical and social
impacts of this devastating disease (Marques et al., 2010).
Sporadic (SAD) and familiar form (FAD) of AD
AD patients can be categorized as having sporadic and familiar forms of AD. Most
cases (95 %) of AD are classified as the sporadic form of AD (SAD), which usually
occurs only in the elderly, after the age of 60 (late-onset). A minor proportion of
cases  (5  %)  are  classified  as  the  familiar  form  of  AD  (FAD),  which  usually  occurs
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before the age of 60 (early-onset) (Marques et al. 2010). Table 1 summarizes the major
genes that are linked to AD. These genes are involved in the production, clearance,
or uptake of A? peptide. The dominant mutations (missense) appear in genes which
encode APP (chromosome 21), presenilin 1 (PSEN 1) (chromosome 14), and
presenilin 2 (PSEN 2) (chromosome 1). Patients who carry this type of mutation
acquire AD symptoms under middle age (early-onset AD). Currently there are no
specific  gene  mutations  linked  to  late-onset  AD.  The  only  evident  risk  so  far  to
acquire late-onset AD is aging. The expression of apolipoprotein E (ApoE) 4 allele
instead of ApoE 3 allele increases the risk of AD more than seven fold (Corder et al.,
1993; Selkoe et al., 2001; Ashford 2004). The role of allele e4 is not fully elucidated,
but it has been suggested to be important in A? clearance (Reiman et al., 2009).
Using a relatively new approach called genome-wide association study (GWAS), a
number of genes, in addition to ApoE e4, have been identified that may increase a
person´s risk for late-onset Alzheimer´s, including BIN1, CLU, PICALM and CR1
(Shi et al. 2012). Some non-genetic risk factors linked to sporadic AD are
hypertension, diabetes, and obesity (Beydoun et al., 2008; Holscher 2011; Wysocki et
al., 2011). Interestingly, no matter which type of AD (sporadic or familiar), the
typical pathological features are remarkably similar.
Table 1. Confirmed genetic factors linked to AD (modified from Selkoe, 2001).
Chromosome Gene defect    Phenotype
21 ?-APP mutations                          A? ?
14 Presenilin 1 mutations     A?1-42 ?
1 Presenilin 2 mutations     A?1-42 ?
19 ApoE4 polymorphism     A? ?
2.3.2 Proteins involved in AD pathology
Amyloid precursor protein (APP) and the formation of ?-amyloid (A?)
Currently, the most dominant hypothesis concerning the pathogenesis of AD is “the
amyloid cascade hypothesis” which suggests that the overproduction of ?-amyloid
(A?) and/or total amyloid load causes toxic effects and leads to neuronal dysfunction
and finally neuronal death (Walsh and Selkoe 2007). A? is the natural product of
metabolism and it is produced by proteolytic cleavage of APP. APP is a membrane
spanning glycoprotein which consists of 695 to 770 amino acids (Selkoe 2001). APP is
generated in the endoplasmic reticulum (ER), transported through the Golgi
apparatus and then transported to the cell membrane (Xu et al., 1997; Hartmann et
al., 1997). APP gene is located on choromosome 21 (Goate et al., 1991).
   On the cell surface, APP is either cleaved by specific secretases or degraded via the
endosomal/lysosomal degradation pathway (Nordstedt et al., 1993; Caporaso et al.,
1994). Specific secretases, which are involved in the cleavage of APP precursors are
?-, ?- and ?- secretases. APP cleavage begins with ?-secretase or ?-secretase which
then leads to nonamyloidogenic or amyloidogenic pathways, respectively (Figure 3).
The first step in the generation of A? (amyloidogenic pathway) is the cleavage of
APP with ?-secretase when sAPP? is released into extracellular fluid. The remaining
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fragment in the plasma membrane is then cleaved by ?-secretase resulting in A?
peptides. The size of A? peptides varies from 39 to 43 amino acids. The most
important  and common forms of  A?s  are  A?1-40 and A?1-42, the  latter  being also  the
most amyloidogenic form of A?. Compared to A?1-40 form, A?1-42 is  more
hydrophilic, fibrillogenic, and thus a more easily aggregating form (Zhao et al., 2004;
Zhao et al., 2007; Chow et al., 2010; Wang et al., 1996). The nonamyloidogenic
pathway does not produce A?. Cleavages of APP by ?- and ?-secretases result in a
p3 peptide, secreted ectodomain sAPP?, and APP intracellular domain (Ring et al.,
2007; Chow et al., 2010). When A? is released in monomeric form, it undergoes
spontaneous conformational changes starting from soluble fragments, which
aggregate to oligomers and finally form large A? fibrils or so called A? plaques
(Querfurth and LaFerla 2010).
Figure 3. APP cleavage products in non-amyloidogenic (blue arrow) and amyloidogenic
(yellow arrow) pathways. The non-amyloidogenic pathway involves cleavages of APP by
?- and ?-secretases and results in long secreted APP (sAPP?) and C-terminal fragments
(purple).  The  amyloidogenic  pathway  involves  cleavage  by  ?-  and  ?-secretases  and
results in long secreted APP (sAPP?), C-terminal fragments (purple protein domain) and
??s (yellow protein domain). A? oligomerizes and then fibrillizes leading to formation of
?? plaques and AD pathology (modified from Chow et al., 2010).
   However, the mutation located just before the ?-secretase cleavage site and after ?-
secretase or ?-secretase cleavage sites of APP are quite rare (familiar AD) and appear
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only in about two dozen families wordwide. Another way to develop AD pathology
is the overproduction of structurally normal APP. As an example, Down syndrome
(trisomy 21) patients have elevated gene dosage of APP and frequently develop AD
pathology in old age (Selkoe, 2011).
   While accumulation of oligomeric A? is clearly associated with dementia, the
function of its monomeric form is not well understood. Moreover, the physiological
functions of the secreted APPs (sAPP? and sAPP?) are also poorly understood. The
secreted sAPP? has been suggested to be subsequently processed by unknown
proteases. The resulting ligand may then bind to death receptor DR6, which in turn
activates caspase-6. This sAPP? driven caspase-6 activation is thought to be involved
in axonal pruning during embryogenesis (Nikolaev et al., 2009). Because sAPP?
seems to be involved in cell death, it is speculated that this pathway could also
contribute to AD pathogenesis. Contrary to sAPP?, sAPP? seems to have a
neuroprotective role and synapse promoting activities (Bandyopathyay et al., 2007).
Some studies have shown that sAPP? has a role in neuronal plasticity and survival
(Mattson et al., 1993; Furukawa et al., 1996). In in vitro models sAPP? has been
shown to act as a growth factor by increasing cell proliferation, cell mobility and
differentiation of many types of cells (Pietrzik et al., 1998; Sabo et al., 2001; Saitoh et
al., 1989). Recently, it was demonstrated that sAPP? affects the proliferation of NPCs
as well (Demars et al., 2011), possibly directing their differentation towards astrocyte
lineage (Kwak et al., 2006; Kwak et al., 2010). Similar effects were also seen in NPCs
when transplanted into APP and A?-rich environments in vivo (Marutle et al., 2007),
thus suggesting that application of stem cell therapy to replace lost or dysfunctional
neurons in neurodegenerative diseases, such as AD may not be straightforward.
?? toxicity
Although the formation of A? is quite well understood, the mechanisms which make
?? toxic to neurons remains elusive. In AD, A? plaques, as well as NFT, are usually
detected in the cortex, hippocampus, basal forebrain, and amygdala (Mattson et al.,
2004). Analysis of post-mortem AD brain has shown that the loss of synapses and
neurite damage occur typically near the A? plaques, indicating that accumulation of
fibrillar A? has a direct neurotoxic role (Pratico and Trojanowski 2000). This is
supported also by in vitro studies  showing  that  fibrillar  A? contributes  to  early
dendritic and synaptic injuries leading to neuronal dysfunction (Walsh et al., 2002).
Fibrillar A? has also been shown to activate microglia to produce inflammatory
mediators  such  as  nitric  oxide  and  reactive  oxygen  species  (ROS),  which  then
facilitate neuronal death (Akiyama et al., 2000; Kitazawa et al., 2004).
   However, the magnitude of A? plaques correlates poorly with cognitive
disturbances. More recent analyses suggest that A?-mediated neurotoxicity might be
highly dependent on the conformation stage of A? (Aizenstein et al., 2008; Pike et al.,
2007) and, as already mentioned, the peptide length affects A? toxicity substantially.
The most neurotoxic form of A? has been shown to be soluble oligomers and
intermediate amyloids (Walsh and Selkoe 2007). Cognitive defects in AD brain
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correlate  better  with  the  levels  of  A? oligomers  compared  to  the  number  of  A?
plaques (Lue et al., 1999). Dimeric and trimeric forms of A? have been shown to be
toxic for synapses (Walsh et al., 2005; Klyubin et al., 2008). In addition, soluble
oligomeric A? has been shown to be more toxic than the fibrillar form (Tomic et al.,
2009).
   In addition to the obvious A? toxicicity to mature neurons, A? appears to have
effects also on proliferation, migration, and differentiation of endogenous NPCs.
Several studies have been carried out in vitro by using synthetic A? to evaluate the
impact  of  A?1-42 and  A?1-40 on NPCs. These results are quite variable which is
possibly due to different forms or preparations of A? or its concentrations applied to
the cells. Both A?1-40 and A?1-42 have been shown to stimulate proliferation of NPCs.
??1-40 has  also  been  found  to  promote  neuronal  differentiation,  whereas  A?1-42 has
been reported to promote the differentiation towards the astrocyte phenotype (Chen
and Dong 2009). Lopez-Toledano and Shelanski (2004) have reported that A?
treatments do not disturb proliferation and differentiation of NPCs and in fact, A?1-42
but not A?1-40 treatment may even have neurogenic effects. The opposite effects have
also been reported; A?1-42 impairs the proliferation, migration, and neuronal
differentiation of cultured NPCs (Haughney et al., 2002a; Haughney et al., 2002b).
Importantly, Mazur-Kolecka and coworkers (2006) showed that A?1-40 impaired
migration of human NPCs. Also, endogenous neurogenesis has been shown to be
altered both in transgenic AD mouse models and also in human AD brain when
analyzed from postmortem tissues. These studies reported controversial results of
increased and decreased neurogenesis in AD (Jin et al., 2004; Boekhoorn et al., 2006;
Taniuchi et al. 2007; Wen et al., 2004; Ermini et al., 2008; Verret et al., 2007; Zhang et
al., 2007).
   Cells have protective systems against A? toxicity. For example, many proteases,
including neprilysin and insulin-degrading enzymes (IDE), are known to regulate
the  levels  of  A?.  Neprilysin  is  a  membrane-anchored  zinc  endopeptidase  which
degrades both monomeric and oligomeric forms of A? (Kanemitsu et al., 2003) and
the  reduction  of  this  enzyme  directly  affects  the  accumulation  of  A? (Iwata  et  al.,
2001). IDE is a thiol metalloendopeptidase, which is known to degrade various small
peptides such as A? (Qiu et al., 1998). In mice, the deletion of IDE has been shown to
lead to an over 50 % reduction of A? degradation (Farris et al., 2003). On the
contrary, overexpression of both degrading enzymes leads to increased A?
degradation and reduced brain A? levels (Leissring et al., 2003).
Neurofibrillary tangles (NFTs)
Another histopathological hallmark observed in AD brain is the accumulation of
intracellular  NFTs  (Kosik  et  al.,  1986).  NFTs  consists  of  tau  protein,  which  is  the
major neuronal microtubule associated protein. In cells, tau binds to the
microtubules, regulates their growth and shrinkage, and thus stabilizes the neuronal
cytoskeleton  (Burbank  and  Mitchison  2006).  In  the  normal  brain,  tau  protein  is
phosphorylated  with  numerous  kinases,  which  usually  exist  in  soluble  forms  in
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axons. In various neurodegenerative disorders, tau protein becomes
hyperphosphorylated and subsequently becomes insoluble, then begins to
aggregate, and finally forms NFTs (Hanger et al., 2009). Phosphorylated forms of tau
protein  reduce  its  affinity  to  microtubules,  and  prior  to  NFT  formation,  it  may
interfere with protein function, which again is important in axonal transport and
contributes to synaptic dysfunction and degeneration of neurons (Mandelkow et al.,
2003; Roy et al., 2005).
   The mechanism which leads to hyperphosphorylation of tau protein is not
completely understood. It is speculated that hyperphoshorylation is caused by up-
regulation or abnormal activation of tau kinases, mutation of tau gene or covalent
modification  of  tau  protein.  Furthermore,  indirect  events  such  as  A?-mediated
toxicity, OS and inflammation may have negative effects also on tau protein
(Ballatore et al., 2007; McNaull et al., 2011).  It is known that various kinases are
involved in tau phoshorylation. Such kinases include: glycogen synthase kinase 3?
(GSK-3?), cyclin-dependent protein kinase-5, protein kinase A, calcium/calmodulin-
dependent protein kinase II, casein kinase-1, mitogen-activated protein  kinase
ERK1/2, and stress-activated protein kinases (Iqbal et al., 2005, 2009; Sengupta et al.,
2006). In addition, increased NFT burden may have an effect on immune responses.
Although the relationship between A? deposition and tau aggregation is not
completely known, it is certain that hyperphoshorylation of tau is linked to
neuroinflammation and is thus involved in the progression of AD (Lee et al. 2010).
2.3.3 Neuroinflammation
One of the main pathological features of AD is chronic inflammation. In the AD
brain inflammatory response in neurons, so called neuroinflammation, it is thought
that  accumulation  of  A? deposits  and  NFT  leads  to  neuroinflammation.  Both  A?
deposition and NFT activate inflammatory cells to produce several pro- and anti-
inflammatory mediators, some of which may also have neurotoxic properties.
Important inflammatory cells in the brain are microglia and astrocytes, in certain
cases also the macrophages and lymphocytes, and the main released
immunomediators are cytokines, chemokines, and ROS (Tansey et al., 2007;
Akiyama et al., 2000). Immunomediators are known to recruit monocytes and
lymphocytes as well as activate microglia and astrocytes to proliferate and produce
more inflammatory factors (Lossinsly and Shivers, 2004; Das and Basu, 2008).
   Microglia are the first activating inflammatory cells, which then orchestrate the
other endogenous immune responses. They express major histocompatibility
complex type II and produce pro-inflammatory cytokines, chemokines, ROS,
complement protein and extracellular proteases (Moore and O´Banion, 2002). One of
the main functions of microglia is their phagocytic property (Streit et al., 1999). In the
AD brain A? plaques attract microglia. There are scavenger receptors at the surface
of microglia which then interact with A? by forming the adhesion between microglia
and A? plaque. After interaction with opsonized A?? microglia phagocytize A?.
However, this process may result in the upregulation of pro-inflammatory mediators
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and  ROS  production  which  then  further  contributes  to  OS  and  neuroinflammation
(El Khoury et al., 1996). Another method microglia internalizes extracellular A? is
through fluid phase macrocytosis. The mechanisms of macrocytosis are different
than phagocytosis or receptor-mediated endocytosis. The macropinocytose vesicle is
formed by the enclosure of membrane ruffles and this vesicle formation is
dependent  on  cytoskeletal  structures  consisting  of  both  actin  and  tubulin.  After
internalization, A? goes to endolysosomal compartments and is degradated
(Mandrekar et al., 2009).  Microglia also release IDE, which acts as a protease capable
of cleaving small proteins, such as insulin and glucagon. As already mentioned, IDE
also degrades A? (Qiu et al., 1998; Qiu et al., 1997). IDE missense mutations in type 2
diabetes mellitus diminish IDE secretion and lead to disturbed A? degradation
(Farris et al., 2004).
   Another important inflammatory cell type is astrocytes, which are also the most
common cells in the brain. Astrocyte functions in the CNS are not completely
elucidated  but  they  are  known  to  support  the  endothelial  cells  of  the  blood  brain
barrier,  supply  nutrients  and  growth  factors  to  nervous  tissue,  and  maintain
extracellular ion balance. In the injured brain and spinal cord, astrocytes heal the
brain by forming a ´glia scar´ and secrete proinflammatory and anti-inflammatory
molecules (Tuppo and Arias 2005). In AD brain, A? plaques have been shown to
induce to development reactive astrocytes (Dickson 1997), which similar to
microglia, secrete chemokines, cytokines, and neurotoxic ROS (Johnstone et al., 1999;
Smits et al., 2002) as well as surround A? plaques and play a role in A? clearance
and degradation by phagocytosing A? deposits (Wyss-Coray et al., 2003; Koistinaho
et al., 2004). Recently, it was shown that when transplanted into the brain of AD
mice, the astrocytes migrate near the A? deposits and phagocytize A?. These results
indicate astrocytes play an important role in A? clearance and may thus provide one
alternative therapeutic approached for AD (Pihlaja et al., 2008; 2011).
2.3.4 Oxidative stress (OS)
During normal oxygen metabolism, several by-products are generated in all aerobic
organisms. These molecules such as superoxide, hydrogen peroxide, and hydroxyl
radicals  are  collectively  called  ROS;  and  they  have  an  important  role  in  cell
signaling. Cells have mechanisms to keep the amount of ROS in equilibrium, but in
situations when ROS production exceeds the cellular recovery capacity, intracellular
OS increases. Accumulation of ROS causes cellular damage, which finally trigger
both necrotic and apoptotic cell death (De Vries et al., 2008). In more detail,
accumulation of ROS affects directly membrane lipids, proteins, DNA, RNA, and
leads to damage in membrane structures, proteins and nucleic acids (Zhu et al.,
2006). Furhermore, oxidation of cytoplasmic protein decreases the antioxidative
defense machinery (Rodrigues Siqueira et al., 2005) and causes damage in the
mitochondrial DNA respiratory chain (Wang et al., 2005).
   Accumulation of ROS inside cells leads to activation of cellular defensive
mechanisms. Various endogenous antioxidant enzymes are responsible for
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maintaining the redox balance inside cells. ROS production is known to induce the
transcription of various cytoprotective enzymes, which all share a common
promoter element called antioxidant response element (ARE). ARE is an enhancer
sequence which controls  the  expression of  both basal  and induced genes.  All  these
induced genes are responsible for detoxification of oxidative stress, xenobiotics,
heavy metals, or ultraviolet light (Kaspar et al., 2009; Nquyen et al., 2009; Rushmore
et al., 1991) and belong to phase II enzymes and antioxidant proteins. One important
phase II enzyme is glutathione S-transferase (Lee et al., 2005).
Keap-Nrf2-ARE pathway
The activation of the transcription of detoxification and antioxidant genes during OS
is dependent on the activation of nuclear factor E2-related factor 2 (Nrf2). Nrf2
proteins belong to the cap ´n´ collar subfamily of basic-region leucine zipper
transcription factors (Itoh et al., 1997) and contain cis-acting element(s) ARE. Under
normal  conditions,  Nrf2  is  expressed  in  a  constitutive  manner,  degraded  within
minutes and mainly kept in cytoplasm rather than nucleus (Figure 4). A cytoplasmic
Kelch-like ECH protein 1 (Keap1) has an important role for the activation and
stabilization of Nrf2. Under normal conditions, Keap1 acts as a Nrf2 repressor by
binding to it and promotes its proteasomal degradation. When the ROS production
is increased, Keap1 loses its activity and allows Nrf2 to dissociate from Keap1.
Released Nrf2 passes into the nucleus, binds to the ARE element and then activates
gene transcription of important antioxidant enzymes. After the cellular ROS
production is  returned back to  normal,  Nrf2  dissociates  from the  nucleus  and gets
degraded (Baird and Dinkova-Kostova 2011; Dinkova-Kostova et al., 2002; Itoh et al.,
2003).
   Previous in vivo and in vitro studies have shown that Nrf2 plays a central role in the
regulation  of  gene  expression  of  various  detoxification  enzymes  and  antioxidant
genes. In vivo, Nrf2-deficient mice have shown lower basal levels of gene expression
of those detoxification enzymes and antioxidant genes and also lack the ability to
induce those genes. These studies also showed that Nrf2 deficiency led to higher
vulnerability to OS-induced damages and the effects of carcinogens (Chan and Kan,
1999; Chan et al., 2001; Khor et al., 2006). In vitro studies  showed  that  in  cultured
Nrf2  deficient  fibroblasts,  the  glutathione  levels  were  decreased  which  was
associated with higher sensitivity to OS (Kwong et al., 1999; Chan and Kwong, 2000).
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Figure 4. A schematic model of regulation of the Keap1-Nrf2 pathway in basal state and
after induction (modified from Baird and Dinkova-Kostova 2011).
Oxidative stress and Alzheimer´s disease
High level of polyunsaturated fatty acids, high oxygen consumption, and low levels
of antioxidants make the CNS extremely vulnerable to OS (Floyd and Hensley, 2002;
de Vries et al. 2008). OS is known to be increased in normal aging. Aging not only
increases the amount of ROS, but also impairs the cellular defense mechanisms
against them (Katzman 1986). ROS are mainly produced in mitochondria and
because of close proximity to the ROS production site, mitochondrial DNA is
especially vulnerable to ROS-induced injuries. Malfunctioning mitochondria and
defects in mitochondrial DNA, may cause declines in mitochondrial functions and
simultaneously further increase ROS production (Lin and Beal, 2006).
   OS is associated with pathogenesis of AD and many other neurodegenerative
diseases such as PD and Huntington disease (Halliwell 2006). In AD, brain OS is
thought  to  play  an  important  role  in  progression  of  disease.  Production  of  A? has
been shown to be induced in OS both in vitro and in vivo (Hensley et al., 1994; Mark
et al., 1997; Murakami et al., 2005; Tabner et al., 2005), and vice versa, increased OS
has been shown to induce the production of A? which again contributes to the
progression of disease (Paola et al., 2000). OS is believed to exist before A? formation
and thus could be the earliest sign of developing AD (Nunomura et al., 2001).
Importantly, the effect of OS has been shown to be increased in AD brain, not only
due  to  increased  production  of  OS,  but  also  because  the  antioxidant  defense
mechanisms are weakened (Katzman, 1986). The levels and activation of
cytoprotective enzymes superoxide dismutase and glutathione peroxidase have been
shown to be decreased in the AD mice (Olcese et al., 2009). In human AD, the brain
levels of hippocampal Nrf2 is reduced (Ramsey et al., 2007) and in hippocampal
neurons, Nrf2 is localized preferentially in cytoplasm rather than in nucleus. These
results suggest that induction of Nrf2-mediated transcription may be disturbed
during OS in AD brain (De Vries et al., 2008).
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Nrf2 and therapeutic potential for AD
It has been reliably demonstrated that Nrf2 response is an inducible and highly
protective  mechanism  against  OS  and  various  toxic  compounds.  These  findings,
together with the hypothesis that the Nrf2-ARE pathway is impaired in AD brain, as
well as the notion that OS is important in the pathogenesis of AD, provide the basis
for the idea that the Nrf2-ARE pathway may be a potential target for the
development of new therapeutic approaches against OS to alleviate AD. For
therapeutic purposes, a cells’ own Nrf2-mediated defense system could be induced
by using small  doses  of  Nrf2  inducers,  enhance the  amount  of  Nrf2  by using Nrf2
overexpressing cells, or inject Nrf2 directly into the brain.
   Several in vitro and in vivo studies  support  the  hypothesis  that  Nrf2  could  be  a
useful target for future treatment. First, cultured astrocytes and neurons lacking
Nrf2 have increased vulnerability against OS (Lee et al., 2003), and when the Nrf2 is
induced, cultured neurons have higher susceptibility to OS or mitochondrial toxins
(Calkins et al., 2005; Jakel et al., 2005; Lee et al., 2003; Shih et al., 2003). In vivo results
are  in  line  with  in vitro studies; Nrf2-deficient mice were more sensitive to OS and
toxins (Calkins et al., 2005) and induction of their own Nrf2 defense mechanisms
protected against neurotoxicity (Burton et al., 2006; Chen et al., 2009; Jakel et al.,
2007; Kraft et al., 2006; Satoh et al., 2006, Satoh et al., 2008; Shih et al., 2005a and b).
Kanninen and coworkers (2008) have demonstrated that overexpression of Nrf2
protected cultured neurons against A? toxicity and Frautschy and coworkers (2001)
demonstrated that the antioxidant treatment resulting in various responses,
including induction of Nrf2, also relieved cognitive defects in an AD mouse model.
Furthermore, lentiviral Nrf2 injections into the hippocampus of AD mouse brain
caused significant alleviation in memory deficits. However, the mechanism behind
this is unknown, but it is suggested that the direct delivery of a Nrf2 gene probably
saturates Keap1 and allows Nrf2 to translocate into the nucleus and further induce
the expression of  cytoprotective  genes  (Kanninen et  al.,  2009).  The amount  of  Nrf2
could be also increased by transplanting Nrf2-overexpressing cells into the brain.
Transplanted Nrf2-overexpressing astrocytes and NPCs, which then differentiated
into astrocytes, were shown to be beneficial for the protection of neurons against
malonate-induced lesions (Calkins et al., 2005; Calkins et al., 2010).
   As  previously  discussed,  one  therapeutic  approach  for  AD  could  be  stem  cell
therapy. High OS level in the AD brain environment have clear effects on survival,
proliferation, migration, and differentiation of transplanted NPCs and therefore
could reduce therapeutic effectiveness. One strategy to prevent OS-related injuries
could be to transplant Nrf2-overexpressing NPCs which then probably are more
sustainable against OS-related injuries.
   Several studies clearly have shown that Nrf2 is the master regulator of the
endogenous antioxidant response. However, further protective roles of Nrf2 were
also reported earlier. Nrf2 was shown to inhibit Fas-mediated apoptosis (Kotlo et al.,
2003; Su et al., 2003) and induce the expression of a class of proteosomal proteins,
which  have  an  important  role  in  removal  of  aberrantly  modified  protein  and  thus
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protein aggregation (Kwak et al., 2003; Park et al., 2009). In addition, Nrf2 was
shown to attenuate inflammatory response (Li et al., 2008) as well as over-
production of proinflammatory mediators (Koh et al., 2009). In 2009, Zhao and
coworkers published interesting results, in which they showed that the
overexpression of Nrf2 promotes neuronal differentiation whereas the inhibition of
endogenous Nrf2 results in opposite effects. These results indicate that if Nrf2 has a
role in neuronal differentiation in cell replacement therapy, the up-regulation of
Nrf2 not only protects against OS, but also may stimulate NPCs towards the
neuronal lineage and offer extra benefits for the treatment of neurodegenerative
disorders.
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3 Aims of the study
Multipotent NPCs provide excellent tools to study the mechanisms of developing
neuronal cells in vitro both in normal situations as well as in genetic disease. NPCs
are  also  a  source  for  cell  transplantation,  which  could  be  a  future  therapeutic
approach for severe neurodegenerative disorders such as AD. NPCs could be used
for  therapeutic  purposes  also  by  stimulating  a  patient’s  own  endogenous  NPCs
directly in order to replace damaged neurons. The differentiation of NPCs is
regulated by various factors, which are not well characterized and are of utmost
importance to be identified before any therapeutic use of NPCs. One intriguing
regulator could be classical neurotransmitters, that others have suggested to play an
important role in maturation of NPCs. In addition, it is certain that the genetic
background has effects on behavior of NPCs. Mutations that cause FXS and AD may
also alter the function of NPCs. Genetic background also matters when using iPS
derived NPCs created from a patient´s own cells, assuming that the mutation alters
the  behavior  of  transplanted  NPCs.  Moreover,  the  altered  brain  environment  in
disease could cause unwanted effects on transplanted NPCs. In AD brain, both A?-
and  OS-rich  environment  may  affect  the  behavior  of  transplanted  NPCs.  The
alleviation of OS related damages could also be beneficial in stem cell therapy.
The aims of this thesis were:
1. To assess whether FMRP deficiency affects the differentiation of mouse and
human NPCs.
2. To study the role of neurotransmitters involved in the regulation of an early
stage of NPC differentiation.
3. To assess whether AD-linked geno- and phenotypes affect the survival,
differentiation  and  migration  of  NPCs in vitro or  after  transplantation  to  the
brain.
4. To assess whether the transcription factor Nrf2 has protective effects against
?? toxicity in cultured NPCs and whether Nrf2 plays a role in neurogenesis.
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4 Materials and methods
4.1 BRAIN TISSUE (I-IV)
Neural stem/progenitor cells (NPCs) were generated from mouse hippocampus,
mouse lateral ventricle, or human fetuses (lateral ventricle). Animal experiments
were conducted according to the national regulation on the usage and welfare of
laboratory animals and approved by the Animal Experiment Committee in the State
Provincial Office of Southern Finland. Postmortem human fetal tissue was obtained
in accordance with the guidelines of the National Institute of Health, the government
of Finland, and the local ethics committee of the Kuopio University Hospital. All
investigations were conducted according to the principles of the Declaration of
Helsinki.
   NPCs were isolated from wt mice or transgenic Fmr1 KO (Bakker et al., 1994),
APdE9 (Jankowsky et al., 2004), and Nrf2 KO mice (Itoh et al., 1997). Human NPCs
were isolated from aborted 18-week-old Fragile X fetus with a methylated repeat
expansion of 276 – 300 trinucleotide repeats in the 5` untranslated region of the
FMR1 gene, and due to social reasons, aborted control fetuses at 7, 12 and 18 weeks
of gestation which was determined by intrauterine ultrasound examinations. The
developmental  stage  and  genotype  of  the  used  mouse  and  human  NPCs  in  the
different studies are listed in table 2.
Table 2. NPCs genotype, age and source of the NPCs used in vitro studies referred as
number I-IV.
NPC Cell genotype Age Stydy
mouse lv NPC Fmr1 KO and wt E13 I
mouse lv NPC Fmr1 KO and wt P6 I
human lv NPC FXS 18-week-old I
human lv NPC wt 7, 12 and 18-week-old I
mouse lv NPC wt P6 / P7 II
mouse h NPC APdE9 and wt E18 III
mouse h NPC Nrf2 -/- and wt E18 IV
lv = lateral ventricle, h = hippocampal, E = embryonic day, P = postnatal day,
APdE9 = AD transgenic mice, Fmr1 KO = fragile X knockout mouse model,
Nrf2 -/- = Nrf2 mice lacking Nrf2 gene
4.2. ISOLATION AND CULTURE OF NPCS (I-IV)
Tissues (hippocampus or tissue from the wall of the lateral ventricle) was dissected
out from the brain and dissociated with 1.33 mg/ml trypsin (Sigma), dissolved in
Hank´s  balanced  salt  solution  (HBSS,  Gibco,  Life  Technology)  with  2  mM  glucose,
0.7 mg/ml hyaluronidase (Sigma), and 0.2 mg/ml kynurenic acid (Sigma) at 37oC for
30 min. Cells were centrifuged at 1500 rpm for 5 min, resuspended in 0.9 M sucrose
in 0.5 X Hank’s balanced salt solution, and centrifuged at 2000 rpm for 10 min. The
cells were then resuspended in 2 ml Earl’s balanced salt solution (EBSS, Gibco, Life
Technology)  and centrifuged through a  gradient  of  the  same salt  solution with 4%
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bovine serum albumin at 1500 rpm for 7 min. Dissociated cells were then plated in
culture medium (DMEM/F12, Gibco, Life Technology) containing 2 mM L-
glutamine, 15 mM HEPES, 100 U/ml penicillin, 100 mg/ml Streptomycin, B27
supplement, 20 ng/ml epidermal growth factor (EGF,  PeproTech, London, UK), and
10 ng/ml basic fibroblast growth factor (FGF-2, PeproTech, London, UK), and
cultivated at 37°C in a humidified atmosphere at 5% CO2. EGF and FGF-2 mitogens
were added every third day and the culture medium refreshed every 3 - 4 days.
Neurospheres were passaged every 5 - 8 days with papain (0.5 mg/ml, Sigma) and
carefully triturated mechanically by using a Pasteur pipette. NPCs were proliferated
up to 10 passages.
4.3 LENTIVIRAL TRANSDUCTION (III-IV)
For transplantation experiments, enhanced green fluorescence protein (GFP)
expressing  NPCs  were  used.  For  transduction  experiments,  wt  and  APdE9
neurospheres were first dissociated. Single NPCs were infected with a multiplicity of
infection  of  3  at  a  density  of  500  000  cells  /  ml  with  a  lentiviral  vector  carrying  an
enhanced GFP (LV GFP)  (Kanninen et  al.,  2009)  for  18  hours.  During the  infection,
culture media was supplemented with growth factors to keep cells in an
undifferentiated stage. On the following day, the virus-infected media was removed
by centrifugation at 1000 rpm for 1 min. Cells were replated in fresh culture media
supplemented with growth factors and expanded in culture. The transduction
efficiency was about 70 – 80% as analyzed with flow cytometry. To manufacture
Nrf2 overexpressing NPCs, wt NPCs were infected with lentiviral vector carrying a
human Nrf2 (LV Nrf2). The transduction efficiency was analyzed with quantitative
real-time PCR.
4.3.1 Quantitative real-time PCR (IV)
For quantitative real-time PCR, 100 000 LV-Nrf2 transduced NPCs were
homogenized and RNA extracted by using RiboPure Kit (Ambion, Life Technology).
cDNA synthesis was performed by using Random hexamer primer (Fermentas,
Thermo Scietific) and Maxima reverse transcriptase (Fermentas, Thermo Scientific).
The relative Nrf2 expression levels were detected by using qRT-PCR protocol from
ABI PRISM 7700 Sequence directors (Applied Biosystems, Life Technology). The
expression levels were normalized to ribosomal RNA and were in Nrf2 transduced
cells about 1000 x higher compared to control cells.
4.4 IN VIVO EXPERIMENTS (I, III-IV)
4.4.1 Animals
Animal experiments were conducted according to the national regulation of the
usage  and  welfare  of  laboratory  animals  and  approved  by  the  Animal  Experiment
Committee in State Provincial Office of Southern Finland. For all in vivo experiments,
31
age- and weight –matched adult male mice were housed under a 12 h light-dark
cycle and given food and water ad libitum throughout the study. For cell proliferation
analysis (study I),  pregnant (E13) Fmr1 KO and their wt littermate mice were used.
For the transplantation experiment (III), 4, 9 and 18 month-old transgenic APdE9
mice expressing familiar AD-linked APP Swe and PS1dE9 mutant genes (APP/PS1)
(Jankowsky et al. 2004) and their wt littermates were used. For kainic acid (KA)
injection (study IV),  Nrf2 -/-  (Nrf2 KO) and wt mice were used. All mice were in a
C57BL/6J genetic background.
4.4.2 Intracerebral NPC transplantation (III)
For  intracerebral  NPCs,  transplantation  GFP  positive  APdE9  and  wt  NPCs  were
used. Single NPCs were resuspended in PBS to obtain a final cell density (100 000
cells/µl) and injected immediately into the mouse hippocampus. Mice were
anesthetized with isoflurane (5% for induction and 1.8% for maintenance of surgical
anesthesia) and immobilized in a stereotaxic apparatus (Kopf Instruments, USA).
NPCs were injected uni- or bilaterally in the volume of 2 µL at the speed of 0.25 µL /
min. The following coordinates were used: +0.32 cm ML, -0.27 cm AP, and -0.27 cm
DV.  The  injection  needle  was  held  still  for  10  min  before  lifting  it  up.  The  wound
was closed with sutures and the animals were monitored until they regained full
consciousness.
4.4.3 BrdU injections (I, IV)
For  detection of  proliferation of  transplanted NPCs,  BrdU were  dissolved in  saline
and  administered  intraperitoneally  (i.p)  at  a  dose  of  50  mg  /  kg  every  24  h  for  the
first seven days. To investigate the production of new cells in the embryonic fmr-1
KO and wt, brain, BrdU was administered to pregnant mice at a dose of 100 mg / kg
every 12 h for four days. BrdU-GFP-NPCs and BrdU expressing cells were detected
in brain sections by immunostaining.
4.4.4 Kainic acid injections (IV)
Kainic acid (KA) is known to induce endogenous neurogenesis in mice (Jessberger et
al., 2005; Choi et al., 2007; Jaako et al. 2009). In this study, i.p injection of KA (Sigma,
dissolved in 0.9 % NaCl) with a dose of 15 mg / kg was given to Nrf2 KO (n = 17) and
wt (n = 14) to induce neurogenesis. Animals in the control groups were injected with
an equal volume of 0.9 % NaCl as a vehicle into Nrf2 KO (n = 8) and wt mice (n = 9).
After injection, mice were monitored for seizure-associated behavior and 4 Nrf2 KO
and  7  wt  mice  without  seizure  associated  behavior  were  excluded  from  further
observations. Additionally 4 Nrf2 KO mice died within 2 h after KA injection.
4.4.5 Brain processing (III – IV)
Mice were terminally anesthetized with Avertin 4 - 8 weeks after NPC
transplantation and 9 d after KA injection and transcardially perfused with
heparined saline (2,500 IU/L) for 2 min before removing the brain. Thereafter, the left
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hemisphere was dissected, postfixed by immersion in 4 % paraformaldehyde (PFA)
solution for 21 h at 4 °C and cryoprotected in 30 % sucrose for 48 h. Then, both left
and right hemispheres were frozen in liquid nitrogen and stored at – 70 °C until later
use.  Coronal  20-µm-thick  sections  were  cut  with  a  cryostat  throughout  the
hippocampal formation (Leica Microsystems GmbH, Germany).
4.4.6. Immunocytochemistry for brain slices (III – IV)
Free floating brain sections were washed with 0.1 M PB pH 7.4 for 6 x 30 min,
transferred to glass slides and air-dried for 20 min. After rehydration sections were
permeabilized with 0.4 % Triton X-100 in PBS for 30 min and washed for 3 x 5 min in
PBS with 0.5 % Tween (PBST) pH 7.4 before blocking unspecific sites using 10 %
normal goat serum (NGS, Chemicon International, Millipore) or a mouse-on-mouse
blocking solution (MOM, Vector Laboratories, UK). The sections were incubated
with  primary  antibodies  prepared  in  5  %  NGS  PBST  at  RT  with  slow  agitation
overnight. The sections were then washed again in PBST for 3 x 5 min before adding
secondary antibodies in 5 % NGS PBST at RT for 2 h and protected from light.  For
double staining, additional primary and secondary antibodies were added
subsequently and stained similarly as the first ones. For detection of the proliferated
NPCs, BrdU/GFP double staining was performed with the following modification in
the staining protocol. After rehydration the brain sections were permeabilized in
precooled ethanol-acetic acid mixture (absolute ethanol and glacial acetic acid 2:1) at
– 20 ? C for 5 min and washed with PBST for 3 x 5 min. Then sections were treated
with 2 M HCl at 37 ?C for 30 min, washed for 3 x 5 min in PBST, and incubated in 0.1
M borate buffer pH 8.5 at RT for 10 min and washed again for 3 x 5 min. Before
adding the primary antibody, sections were treated with 0.5 % MOM-blocking
reagent in PBST for 1 h, and washed for 3 x 5 min. Because HCl treatment abolishes
GFP  fluorescence,  the  sections  were  eventually  stained  with  anti-GFP  antibody.
Primary and secondary antibodies are listed in Table 3.
4.5 IN VITRO EXPERIMENTS (I-IV)
4.5.1 Ca2+ -imaging (I-II)
For the Ca2+ -experiment, several (15 – 25) neurospheres with the diameter on
average of 200 µm were transferred on poly-DL-ornithine (0.5 mg/ml in PBS, Sigma)
or poly-D-lysine (10 µg/ml, Sigma) / laminin (5 µg/ml laminin, GIBCO, Life
Technology) coated cover glasses and differentiated without EGF and FGF for 1 – 8
d. After attachment, single neurosphere cells started to migrate out of neurospheres
and differentiate. After differentiation of the defined time period, the neurospheres
were incubated with 4 µM Fura-2 acetoxymethyl-ester in a Na+ -Ringers solution
(pH 7.4) consisting of (in mM) 137 NaCl, 5 KCl, 1 CaCl2, 1.2 MgCl2, 0.44 KH2PO4, 4.2
NaHCO3, 10 glucose, 1 probenicid and 20 HEPES. Thereafter the coverglasses were
attached to the bottom of a thermostated perfusion chamber and perfused at a rate 2
ml/min (37 ?C). Individual NPCs (10 – 50) from the edge of neurospheres were
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simultaneously recorded using 340 and 380 nm light excitation achieved with a filter
changer  under  control  of  an  InCytIM-2  system  (Intracellular  Imaging  corp.,
Cincinnati, OH) and dichroic mirror (DM430, Nikon). The emission was measured
through a 510 nm barrier filter with a COHU integrating CCD camera. A rationed
(340/380) image was achieved every second. NPCs were challenged with various
substances which elevated intracellular Ca2+. The following neurotransmitters were
used: substance P (SP), neurotensin (NT), oxotremorine (OxoM), ACh, ATP, NE, and
glutamate in the presence and absence of extracellular Ca2+. For depolarization,
NPCs  were  challenged  with  high  potassium  chloride  K+ (70 mM) (Na+ -Ringer
solution was mixed with a Ringer solution where the NaCl is replaced with KCl). For
detection of the type of metabolic glutamate receptors (mGluR), group I mGluR
antagonists MPEP and LY367385 were used (both from Tocris Cookson Ltd., Bristol,
UK).
4.5.2 Cell proliferation, neurite length, and cell body volume analysis (I)
The incorporation of 0.5 µCi/ml (1 Ci = 37 GBq) [3H ]thymidine (GE Healthcare Ltd,
UK) was investigated in cell cultures seeded at a density of 105 cells per ml in culture
media supplemented with growth factors. After 24 h incubation, cells were
precipitated with 50 µl/ml trichloroacetic acid for 20 min at 4 ?C, solubilized in 80 µl
of 1 M NaOH for 20 min at room temperature, and neutralized with 0.25 ml of 1 M
HCl. The radioactivity of the lysates was counted with scintillation fluid (OptiPhase
HiSafe 3) in a liquid scintillation counter (1450 MicroBeta, Wallac).
   To  measure  the  length  of  neurites  and  cell  body  area,  NPCs  were  first
differentiated 1 or 5 days on the cover glasses as a single-cell suspension or as
neurospheres. After Tuj-1 staining the neurons at the outer radius of the
differentiated neurospheres were imaged with 40 and 60 objectives and the length of
neurites  and  cell  body  area  was  measured  by  using  Neurolucida  Software
(NeuroBright Field, VT) or Image Pro Plus (Media Cybergenics,  Silver Spring, MD)
software.
4.5.3 A? treatments (III-IV)
To investigate the effects of A? on proliferation, migration, differentiation, and
survival  of  developing  NPCs,  A?-treatment  assays  were  performed.  For  all
experiments, A?40 or  A?42 peptides (American Peptide, Sunnyale, USA) were
reconstituted in sterile water at a concentration of 155 µM and used immediately
after reconstitution except prefibrillized A?42 which was incubated for seven days at
37 ?C before use.
Proliferation assay
In the proliferation assay, 15 000 single NPCs (after neurosphere dissociation) were
plated into a 96-well plate in the medium supplemented with growth factors (EGF
and bFGF) and different A? peptide preparations. Cells were allowed to proliferate
and form new freely floating neurospheres for 48 hours. Newly formed
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neurospheres were imaged (4xobjective) and the average sizes of neurospheres
(diameter >40µm) were counted. Six to eight replicate images per each concentration
were used.
Migration assay
In migration and differentiation assays, 10 – 15 single neurospheres (average
diameter 200 – 400µm) were transferred to the poly-DL-ornithine (0.5 mg/ml in PBS,
Sigma) coated well plate and allowed to differentiate without additional growth
factors, but in the presence of different A? peptide preparations for 2 – 4 days. For
the evaluation of cell migration neurospheres were imaged as 6 – 8 replicate
neurospheres per each A? concentration (10xobjective). The average migration
distance from the edge of a neurosphere was measured. The 30 farthest migrated
cells per neurosphere were included in migration analysis.
Differentiation assays
For differentiation and viability assays, single NPCs were resuspended at the density
of 200 000 cells / 0.5 ml in growth media and allowed to differentiate in the poly-DL-
ornithine coated well plate without growth factors and with different A?
preparations for 7 days. Differentiated single NPCs and neurospheres were then
fixed by using 4% formaldehyde and immunostained. For analysis, ten replicate
images per each concentration were analyzed. When neurospheres were used,
images (10 or 20xobjective) were taken at the periphery of neurosphere colony area,
where the cells migrated separately.
Viability assays
For  detection  of  dead  and  live  cells,  propidium  iodide  (PI)  (5 µM in DMSO,
Molecular Probes) and SYTO 13 (1 µM in DMSO, Molecular Probes, Life Technology)
were added in culture wells (single NPCs or neurospheres) and incubated for 10 min
at 37?C. Immediately after incubation, cells were imaged (6-8 replicates) and the
number of live and dead cells counted.
   All images were taken by using Olympus IX71 microscope with MT10 illumination
system attached with the DP70 digital camera, running DP software (all from
Olympus).
4.5.4 Immunocytochemistry for NPCs
For characterization of phenotype of differentiated NPCs, fixed cells were first
permeabilized with ice-cold methanol for 20 min and then washed 3 x 15 min with
0.1 M PBS pH 7.4. After each step of this protocol, cells were washed similarly. Next,
non-specific  sites  were  blocked with 20% NGS,  in  PBS for  1  h.  Thereafter,  primary
antibody with 5% NGS was added and incubated over night at RT. On the following
day, secondary antibodies were incubated for 2 h at RT and protected from light. For
double staining, another primary and secondary antibody were used. For nuclear
stainings Hoechst 33342 (2.5µg/ml Sigma) or DAPI (0.1 µg/ml) were used. The
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primary and secondary antibodies used in this study are listed in table 3. After
staining, the wells were filled with PBS for future use and cover glasses were
mounted with SlowFade antifading reagent (Molecular Probes, Life Technology).
Table 3. Primary and secondary antibodies used in immunohistochemistry of cells and/or
brain sections.
Antibody Dilution Manufacturer Use (study)
Primary antibodies
mouse anti-FMRP 1:1000 Euromedex cells (I)
mouse anti-Tuj-1 1:500 Biosite cells (I-IV)
mouse anti-NeuN 1:500 Chemicon cells (I-II)
rabbit anti-GFAP 1:500 Sigma/DAKO                      cells/slices (I-IV)
rabbit anti-Tbr1 1:500 Chemicon cells (II)
rabbit anti-Tbr2 1:500 Chemicon cells (II)
rabbit anti-BLBP 1:500 Chemicon cells (II)
rabbit anti-mGluR5 1:500/1:250 Chemicon cells (I-II)
quinea big anti-GLAST 1:400 Chemicon cells (II)
rabbit anti-Nestin 1:500 Abcam cells/slices (III)
rabbit anti-DCX 1:500 Cell Signaling                      slices (III-IV)
rabbit anti-PanA? 1:300 Biosource slices (IV)
mouse anti-BrdU 1:50 Roche Applied Sciences slices (III)
/Amersham Bioscience cells (I)
rabbit anti-GFP 1:200 BD Bioscience                      slices (III)
mouse anti-CD45 1:100 Serotec slices (III)
TUNEL detection       Chemicon slices (III)
kit
Secondary antibodies
Cy3 1:500 Chemicon cells (I-II)
AMCA 1:250 Jackson Immuno cells (I-II)
Research
Alexa 488 1:500/1:200 Molecular Probes cells/slices (III-IV)
Alexa 568 1:200 Molecular Probes cells/slices (III-IV)
Dylight 405 1:200 Jackson Immuno slices (IV)
Research
4.6 ANALYSIS OF IMMUNOREACTIVITIES
For quantitative analysis, the brain sections and cells from in vitro experiments were
imaged by using fluorescence/light microscope Olympus IX71 equipped with high-
resolution PD70 digital camera running DP software (all from Olympus), AX70
microscope equipped with a digital camera (Color View 12 or F-view, SoftImaging
Systems), laser scanning microscope Zeiss LSM5 Pascal and Leica TCS SP2 AOBS
with subsequent analysis program,  Zeiss LSM 700 confocal microscope and ZEN
2009 light edition analysis program.
   Results are shown as mean ± standard error of mean (SEM). Statistical analysis was
performed by using SPSS software (SPSS Inc Chicago, IL, USA) or GraphPad Prism
software (GraphPad Software, San Diego, CA). For two group comparison Student t-
test was used and for more groups one way and two way ANOVA followed by LSD
or Tukey’s post-hoc test. In addition Mann-Whitney test was used. The statistical
significance is indicated as *p<0.05, **p<0.01 and ***p<0.001.
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5 Results
5.1 FMRP DEFICIENCY HAS IMPACT ON DIFFERENTIATION OF
NPCs (I)
In  study  (I),  we  examined  the  effects  of  FMRP  deficiency  on  human  and  mouse
NPCs. We exploited human and mouse FMRP deficient NPCs isolated from the
brains of a 18-week-old FXS fetus and Fmr1 KO  mice  and  then  compared  the
morphology, differentiation, and Ca2+ signaling  of  FMRP  deficient  NPCs  to  that  of
age-matched wt human and mouse NPCs.
5.1.1 FMRP deficiency alters neuronal differentiation of NPCs
In a differentiation study, both human and mouse FMRP deficient NPCs produced a
significantly higher amount of Tuj-1 positive neurons compared to controls. In more
detail, the morphological analysis of Tuj-1 positive FMRP deficient neurons showed
that those cells have lower number of primary neurites compared to controls.
Furthermore, the length of the longest neurites was significantly less in FMR1
deficient NPCs compared to controls. Next, the average cell body volume was
significantly reduced in FMRP deficient NPCs compared to wt NPCs.
   Another main phenotype of differentiated NPCs was astrocytes, which express
GFAP. The number of GFAP positive astrocytes was significantly lower in
differentiated  FMRP  deficient  NPCs  compared  to  controls.  The  analysis  of  the
number of TUNEL-positive apoptotic cells revealed that, the number of apoptotic
cells was increased in FMRP deficient NPCs in a cell  population that was not Tuj-1
positive. These results may indicate that cell death was increased in a cell population
other than neuronblasts and could explain the lower number of GFAP positive
astrocyte in cells lacking FMRP when compared to wt cells. Taken together, these
results strongly indicate that FMRP deficiency alters the NPCs differentiation to
neurons.
5.1.2 Neurotransmitter responses of differentiating FMRP deficient NPCs
In study (I), we carried out experiments to determine whether neurotransmitters
have a role in differentiation of NPCs and how the FMRP deficiency could affect the
neurotransmitter mediated intracellular Ca2+ ([Ca2+]i) responses. We challenged
differentiated FMRP-deficient and wt NPCs (from mouse) first to glutamate, then
ACh, and last elevated extracellular K+. Between the stimulations, cells were
washed. Glutamate stimulation was performed both in the presence and absence of
extracellular Ca2+ to demonstrate the ionotropic (iGluR) and metabotropic (mGluR)
glutamate receptor responses, respectively. The Ca2+ response to elevated
extracellular K+ demonstrated the presence of voltage-gated Ca2+ channels.
   After 1 day differentiation, the majority (90%) of the NPCs responded to ACh. In
the absence of extracellular Ca2+, NPCs responded to glutamate stimulation in a fast,
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spiky response, which indicates that mGluRs are present. Approximately 30 % of
cells have mGluR responses and these same cells have relatively small response to
elevated K+.  We  classified  the  cells  with  fast  spiky  mGluR  response  (absence  of
extracellular Ca2+) and small K+ response as type 1 NPCs (Figure 6A). Another type
of NPCs was found, as approximately 22 % of cells had robust response to elevated
K+ (>300nM) but lacked the mGluR response (Figure 6B). By using specific antagonist
MPEP for mGluR5 and LY367385 for mGluR1, we demonstrated that differentiating
NPCs express the mGluR5 subtype.
   An interesting finding was that during the ACh stimulation, type I NPCs showed
intracellular calcium [Ca2+]i  oscillations  (4-6  spikes/min)  and  surprisingly,  higher
number of oscillating cells were seen in FMRP deficient NPCs compared to wt NPCs
(3.2-fold) (Figure 6A). Those oscillating cells usually showed also metabotropic
glutamate responses. We also showed that human neurosphere-derived NPCs
responded to ACh and a significant proportion of FMRP deficient human NPCs
responded to ACh with [Ca2+]i oscillations.
Figure 6. Changes in intracellular Ca2+ concentrations in differentiating FMRP deficient
NPCs after exposure of Ach, glutamate (stimulation with or without extracellular Ca2+)
and 70 mM K+. (A) Cells with mGluR responses and small K+ responses are classified as
type I cells. (B) Cells with robust K+ responses are classified as type II cells.
5.1.3 Production of new cells in FMRP deficient mice
For investigations on how in vitro findings correlate with the in vivo situation, the
number  of  newly  produced  cells  in  embryonic  brains  from  wt  and Fmr1-KO mice
were studied after BrdU administration. Mice were given several BrdU injections to
cover a cell cycle during cell proliferation and after 4 days they were sacrificed. We
found  that  the  number  of  BrdU  positive  cells  in  SVZ  was  significantly  higher  in
Fmr1-KO mice compared to wt mice.
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5.2 DIFFERENTIATING NPCs RESPONDED TO NEURO-
TRANSMITTERS (II)
In study II, we identified in more detail various neurotransmitters involved in NPC
differentiation. The neurotransmitter–mediated increases in [Ca2+]i were monitored
after 1 – 8 differentiation days in the NPCs located near the edge of neurospheres as
well  as  farther  migrated  cells  in  the  periphery  of  neurosphere  colony  area.  The
following neurotransmitters (or their receptor agonists), which mobilize [Ca2+]i were
tested: SP, glutamate, NE, ACh, the muscarinic agonist OxoM, ATP, and
depolarization with elevated K+.
5.2.1 Neurotransmitter responses after 1 – 4 day differentiation
In the early stage of differentiation (1 - 4 days), most of the cells (60 - 80%) responded
to ACh/OxoM, NE, and ATP (Figure 5A). In addition, 10 – 50 % of the cells
responded to SP. Many cells also responded to glutamate in the presence of
extracellular Ca2+, which indicate the presence of iGluR responses and in the absence
of extracellular Ca2+,  which  indicate  the  presence  of  mGluR5  responses.  A  more
detailed analysis showed that about 80 % of SP responding cells responded also to
NE and 100 % of SP responding cells also responded to glutamate through mGluR5.
In the early stage of differentiation, the robust response to elevated K+ was  quite
rare. We found only a few cells which responded to elevated K+ with robust
responses and these cells did not show either mGluR5 or SP response. However,
these cells showed a prompt iGluR response.
   Our results indicate that mGluR5 response could be seen only during the first
differentiation days. The proportion of mGluR5 responding cells progressively
decreased when the differentiation time lengthened. On the later phases of NPCs
differentiation, the proportion of cells with iGluR response and elevated K+ response
progressively increased. There was a positive correlation between iGluR and
elevated K+ responses and negative correlation between mGluR and elevated K+
responses.
   These results also indicate that the two types of glutamate receptors (iGluR and
mGluR5) are expressed in different cell types or in different stages of NPC
maturation. Similar to study I, we denoted cells as type I and type II NPCs based on
their glutamate responses. Type I showed fast spiky mGluR5 responses and type II
showed robust responses to iGluR and K+.  In  more  detailed  analysis  of  individual
cells  and  their  spatial  distribution,  only  type  I  cells  were  found  at  the  first
differentiation day regardless of the cells’ spatial distribution. Type I cells were
mainly found near the edge of neurospheres. At the third differentiation day cells
were further dispersed around the neurosphere and type II cells were found in outer
cell layers around the neurosphere.
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Figure 5. Typical  neurotransmitter  responses (A) after  1 – 2,  (B) 3 – 5 and (C) 6 – 8
differentiation days. Glutamate (Glu) stimulations are done in the absence and presence
of extracellular Ca2+.
5.2.2 Neurotransmitter responses after 5 - 6 day differentiation
After  5  –  6  days  of  differentiation many type I  and II  cells  were  identified as  Tuj-1
positive cells (neuroblasts). Many cells near the edge of neurospheres were positive
for a mGluR5 marker even if they did not show mGluR5 glutamate response or the
response was very weak (Figure 5B). At this later phase, a clear spatial pattern of
responsiveness to glutamate was seen. Migrating NPCs seemed to progressively lose
their mGluR5 response. In the periphery of the neurospheres, an almost pure
population  of  type  II  cells  were  found.  Interestingly,  many  but  not  all  of  mGluR5
cells also co-expressed neuronal markers Tuj-1 and NeuN. The mGluR5 cells which
located  near  the  edge  of  neurosphere  were  positive  with  the  radial  glia  marker
GLAST.
5.2.3 Neurotransmitter responses after 8 day differentiation
The differentiation time was further  lengthened and after  8  days  of  differentiation,
cells migrated even longer distances and appeared to have more neuron-like
phenotypes. They lost the responses to SP and NE. Only a few responded to
Ach/OxoM and ATP. Almost all showed a robust iGluR response, most also showed
a robust NMDA and elevated K+ response; and finally, they were identified as Tuj-1
positive cells (Figure 5C). Our results here clearly demonstrate that the cells
expressing mGluR5 represent an early developmental stage which is followed by
progression towards more mature neuronal phenotype.
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5.3 AD MIMICKING GENOTYPE AND ENVIRONMENT AFFECTS THE
SURVIVAL, MIGRATION AND DIFFERENTIATION OF NEURONAL
PROGENITOR CELLS (III)
In  study  III,  we  investigated  the  effect  of  A? both in vitro and in vivo on  NPC
survival, proliferation, migration, and differentiation. For the transplantation
experiment, GFP positive NPCs isolated from wt and transgenic APdE9 mice and
transplanted back into wt and APdE9 (4, 9 and 18-month-old) mouse hippocampus
were used. For in vitro experiments,  wt  and APdE9 NPCs and synthetic  A?1-40 and
??1-42 were used.
5.3.1 Survival and proliferation of engrafted NPCs
Four and eight weeks after transplantation the transplanted NPCs survived well and
showed signs of migration. NPCs typically migrated along the hippocampus fissure,
but in some cases cells remained near the injection site and formed big cell clusters.
Based on the intensity of GFP fluorescence, the highest number of NPCs was found
in 18-month-old APdE9 mice transplanted with APdE9 NPCs. In fact, APdE9 NPCs
survived better in 18-month-old APdE9 mice compared to wt or APdE9 NPCs
transplanted into younger mice. Neither higher apoptosis in wt NPCs, nor younger
mice or higher NPC proliferation in older mice explained the differences between
groups.
5.3.2 Survival and proliferation of A? treated NPCs in vitro
In vitro proliferating NPCs were treated with soluble A?1-40 and A?1-42. Proliferating
NPCs  formed  free  floating  cell  cluster  `neurospheres´  in  the  presence  of  growth
factors. By measuring the diameter of newly formed neurospheres, we showed that
??1-42 treatment reduced the number of large (diameter >40 µm) neurospheres but
the same concentration of A?1-40 did not disturb NPC proliferation. We also
determined the number of live and dead cells after treatment with soluble A?1-42 and
??1-40 treatments. A?1-42 significantly decreased the number of live cells in both
genotypes. Similar effects were also seen in APdE9 NPCs treated with prefibrillized
??1-42.
5.3.3 Migration of transplanted NPCs
Next,  we  evaluated  the  migration  of  NPCs in vivo.  As  earlier  mentioned,
transplanted NPCs typically migrated along the hippocampus fissure. Also
transversal migration was seen towards the CA1 and DG. The lengths of transversal
migration were highly dependent on age and genotype. The migration distance
increased gradually in age and genotype-dependent manner in such a way that the
shortest migration distance was seen in wt NPCs transplanted into wt mice and the
longest distance was seen in APdE9 NPCs transplanted into 18-month-old APdE9
mice. Interestingly, APdE9 NPCs transplanted into 18-month-old APdE9 mice were
thus the most widely spread cells.
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   Next, we explored the hypothesis that the higher migratory activity of APdE9
NPCs  transplanted  into  old  APdE9  mice  could  be  due  to  a  higher  amount  of  A?
plaques in aged brain, which then attracted transplanted NPCs to migrate towards
the plaques. A? plaques are surrounded with both microglia and astrocytes,  which
both are capable to phagocytose A? (Malm et al., 2010). In addition, it was recently
shown  that  transplanted  astrocytes  migrate  into  the  vicinity  of  the  A? plaque  and
also phagocytose A? (Pihlaja et al., 2008). However, we could not find evidence that
??-microglia complexes attracted the engrafted NPCs as only a few of transplanted
cells migrated into the vicinity of A? complexes. NPCs in the vicinity of A? plaques
were not GFAP-positive astrocytes and did not show colocalization of A?
immunoreactive material when analysed with confocal microscopy.
5.3.4 Migration of cultured neurosphere derived NPCs
In in vitro migration assays, we cultured wt and APdE9 neurospheres in the presence
of soluble A?1-40, A?1-42 and prefibrillized A?1-42. The migration distances of single
NPCs were measured from the edge of neurospheres. A?1-42 clearly  inhibited  and
??1-40 increased the migration (at 1 – 5 µM concentrations). A co-treatment with A?1-
42 and A?1-40 showed that  A?1-40 could compensate for the negative effects of A?1-42.
Prefibrillized A?1-42 seemed to lose the majority of its toxicity during fibril formation
and NPCs were able to migrate longer distances compared to the cells treated with
soluble A?1-42, but the cells migrated as large clusters indicating a distinct migration
pattern. Unlike in vivo, wt and APdE9 NPCs migrated quite similarly in vitro.
5.3.5 Phenotype of transplanted NPCs.
Most of the transplanted NPCs were GFAP-positive astrocytes (31 – 33 %) and
doublecortin (DCX) (31 – 42 %) positive immature neurons. The number of DCX-
positive NPCs was slightly, but not significantly, increased when transplanting
APdE9  NPCs  instead  of  wt  NPCs  into  4-month-old  wt  mice.  Similarly,  when
transplanting  wt  NPCs  into  9-month-old  APdE9  mice  compared  to  wt  mice  and
when  transplanting  APdE9  NPCs  into  18-month-old  APdE9  mice  compared  to  wt,
the number of DCX-positive NPC were slightly increased. Opposite effects were
seen when comparing the number of GFAP-positive astrocytes. GFAP-positive NPCs
decreased significantly when NPCs were transplanted into APdE9 mice (regardless
to  cell  genotype or  mice  age)  compared to  NPCs transplanted into  9-month-old wt
mice.
5.3.6 Phenotypes of differentiated NPCs in vitro
In vitro the majority of differentiated NPCs were GFAP-positive cells (55-70%) and
only a minor part of them were Tuj-1-positive (5 - 12%). Interestingly, cell genotype
affected the differentiation of NPCs as a higher number of Tuj-1-positive neurons
was seen in APdE9 NPCs (12%) compared to wt NPCs (8%). After exposure to
soluble A?1-42, the  number  of  Tuj-1-positive  neurons  was  significantly  reduced  in
APdE9 NPCs, but not wt NPCs cultures. An opposite effect was seen after exposure
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to soluble A?1-40 or prefibrillized A?1-42.  Concentrations  as  low as  1  µM A?1-40 and 5
µM  of  prefibrillized  A?1-42 significantly increased the number of Tuj-1 positive
neurons only in APdE9 NPCs. A similar effect was seen in wt NPCs cultures, but at
higher 10 µM concentrations.
5.3.7 Endogenous neurogenesis
We  studied  whether  transplanted  NPCs  could  stimulate  a  mouse’s  own
neurogenesis. In 4-month-old wt mice (PBS-injected control mice) and 6-month-old
wt and APdE9 (no injection) mice, a conciderable number of DCX positive cells was
observed in DG.  When neurogenesis was examined from 9 – 24-month-old mice,
only a few DCX positive cells were seen regardless of the mouse genotype.
Therefore, we suggest that endogenous neurogenesis is decreased dramatically
between 6 – 9-months of age in mice.
   Interestingly, a higher number of DCX-positive cells were found in the hippocampi
of 9-month-old wt and APdE9 mice, which received NPC transplantation compared
to their PBS-injected control mice without transplantation. A similar trend was seen
in aged APdE9 mice. Importantly, also the morphology of DCX-positive cells
changed upon NPC transplantation. DCX-positive cells exhibited neurites whereas
DCX-positive cells in PBS-injected control mice did not. Despite different ages of the
mice  with  NPCs  transplants  and  their  PBS-injected  controls,  we  suggest  that
transplanted NPCs stimulate endogenous neurogenesis.
5.4 NRF2 MEDIATES PROTECTION OF NPCs AGAINST A? TOXICITY
AND PROMOTES ENDOGENOUS NEUROGENESIS (IV)
In study IV, we examined the hypothesis that Nrf2 may have a role in neuronal
maturation using both in vivo and in vitro assays. In addition, we applied in vitro A?
treatment assays and studied whether Nrf2 has a protective role against A? toxicity
in developing NPCs.
5.4.1 Nrf2 promotes NPC proliferation and differentiation in vivo
First, we studied whether Nrf2 is involved in neurogenesis. Wt and Nrf2 knock out
(Nrf2-/-) mice were injected with kainic acid (KA), which stimulated mouse
endogenous NPCs to proliferate and differentiate. To detect proliferating cells and
new neurons 9 days after KA administration, brain sections were stained with a
proliferation marker Ki67 and DCX, a marker of maturating neurons. KA
stimulation  significantly  increased  the  number  of  Ki67  and  DCX  cells  in  the
hippocampus of both wt and Nrf2-/- mice. However, the KA-induced proliferation
and neurogenesis were significantly reduced (27% when using Ki67 marker and 25%
when using DCX marker) in the hippocampi of Nrf2-/- mice, suggesting an
important role of Nrf2 in hippocampal neurogenesis.
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5.4.2 Nrf2 promotes NPC proliferation and differentiation but not migration in
vitro
In vitro assays were performed to confirm our in vivo findings. In the in vitro study,
we compared proliferation, migration, and differentiation of wt NPCs, Nrf2-/- NPCs,
and NPCs transduced with lentiviral vector encoding Nrf2 (Nrf2 overexpressing). In
proliferation assays after 48 hour culture, the average volumes of newly produced
neurospheres were measured. The average volumes (neurosphere diameter >40µm)
of wt and Nrf2-/- neurospheres were approximately 30 % smaller compared to LV-
Nrf2 neurospheres. Next, for migration and differentiation assays wt, LV-Nrf2, and
Nrf2-/- neurospheres were differentiated for 7 days. In the migration assay, the
average migration length was measured after 7 days of differentiation. We found
that  LV-Nrf2  NPCs  migrated  slightly,  but  not  significantly  longer  compared  to  wt
and Nrf2-/- NPCs. The neuronal phenotype of differentiated NPCs (neurosphere
origin)  was  determined by Tuj-1  staining.  Tuj-1  positive  NPCs were  found around
the neurospheres and the number of Tuj-1 positive NPCs was significantly higher in
LV-Nrf2 NPCs compared to wt and Nrf2-/- NPCs. These in vitro results suggest that
overexpression of Nrf2 promotes both proliferation and differentiation but not
migration of NPCs.
5.4.3 Nrf2 counteracts the negative effects of A?1-42 on NPC viability and neuronal
differentiation
Next, we examined whether Nrf2 regulates viability, proliferation, migration, and
differentiation of NPCs when exposed to A?1-42 and A?1-40. A?1-42 exposure reduced
significantly  the  cell  viability  of  differentiated  wt  and  Nrf2-/-  NPCs,  but  did  not
affect LV-Nrf2 transduced NPCs. In the proliferation experiment, A?1-42 reduced the
proliferation  of  both  wt  and  Nrf2-/-  NPCs,  but  the  size  of  LV-Nrf2  transduced
neurospeheres was not changed. A?1-40 treatment reduced proliferation only in Nrf2-
/-  NPCs,  while  in  wt  NPCs,  proliferation  remained  unchanged;  and  in  LV-Nrf2
transduced NPCs, proliferation increased almost by 35%. In the migration assay,
??1-42 treatment reduced migration of all cell types. However, Nrf2-/- NPCs migrated
slightly  shorter  distances  compared  to  wt  or  LV-Nrf2  transduced  NPCs.  In  the
differentiation study, A?1-42 did  not  change  the  number  of  Tuj-1  positive  cells  in
either wt or LV-Nrf2 NPCs, whereas the number of Tuj-1 positive neurons were
reduced 33 % in Nrf2-/-.
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Table 4. Main findings of this thesis.
Study Main findings
I FMRP deficient neurons showed smaller cell body volume, lower number
and shorter primary neurites. Differentiated FMRP deficient NPCs showed an
increased amount of apoptotic cells in the cell population which was GFAP-
positive.  FMRP  deficient  NPCs  showed  a  higher  number  of  cells  which
showed intracellular calcium oscillation during the ACh stimulation.
II At  the early stage of  differentiation (1-4 days),  neurosphere derived NPCs
responded to ACh, NE, ATP, and they had small responses to elevated K+.
Several  cells  had  also  glutamate  (mGluR5)  and  SP  responses.  After  5-6
days  of  differentiation,  the  number  of  mGluR5  responding  cells
progressively decreased and the number of glutamate (iGluR) and elevated
K+ responding cells  increased. After  8 days of  differentiation,  cells  showed
only  robust  iGluR,  NMDA  and  elevated  K+ responses and they were
identified as Tuj-1 positive neurons.
III When  studied  in vivo,  transplanted  NPCs  survived  better  and  migrated
longer  distances  when  transplanted  into  the  hippocampus  of  APdE9  mice
compared to NPCs transplanted into wt mice. In addition, transplanted NPCs
stimulated endogenous neurogenesis even in APdE9 mice. When studied in
vitro, APdE9 NPCs differentiated more into Tuj-1 positive cells compared to
wt NPCs. Synthetic A?1-42 treatment significantly reduced migration of NPCs.
IV When studied in vivo, KA-induced proliferation and endogenous
neurogenesis were significantly lower in the hippocampi of Nrf2-/- mice.
When studied in vitro, Nrf2  overexpressing  NPCs  differentiated  more  and
Nrf2-/-  NPCs  less  into  Tuj-1  positive  neurons  compared  to  wt  controls.
During the A?1-42 treatment Nrf2 overexpressing NPCs had a higher survival,
proliferation, and neuronal differentiation rate than wt controls or Nrf2-/-
NPCs.
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6 Discussion
Human and mouse multipotent NPCs provide a unique cell source for in vitro and in
vivo studies of neural mechanisms in the pathogenesis of various human
neurological disorders. Furthermore, considering that stem cell-based therapy may
be an alternative therapy for many neurodegenerative diseases in the future, NPCs
could represent a potential cell source for such purposes. The potentially therapeutic
effect of NPCs could be obtained either by transplanting them into the affected brain
area or by stimulating a patient’s own NPCs to proliferate and differentiate towards
the type of neuron that has become dysfunctional or is lost during the course of the
disease. Evidently, the mechanisms of NPC production as well as their true effect on
the brain pathology and function need to be carefully investigated before any
therapeutic use or clinical trials could be considered. The purpose of this thesis was
to provide new information about the mechanisms of differentiation of NPCs in
healthy brain as well as in neurological diseases of FXS and AD. The results are
discussed in more detail below.
6.1 FMRP DEFICIENCY HAS EFFECT ON DIFFERENTIATION OF
NPCs (I)
In study I, we carried out experiments to investigate whether FMRP deficiency has
an impact on NPC differentiation. The effects of FMRP deficiency during the early
stage of neuronal differentiation have been poorly understood so far. We showed
that FMRP deficiency alters the morphology, differentiation and the functions of
both  cultured  human  and  mouse  NPCs,  indicating  a  profound  role  of  FMRP  in
development  of  NPCs.  This  conclusion  was  further  supported  by  the  finding  that
FMRP deficient neurospheres differentiated more into Tuj-1 positive neurons and
less into GFAP positive astrocytes compared to controls. Furthermore, FMRP-
deficient neurons had shorter primary neurites and their number was reduced
compared to controls. The Ca2+ imaging data showed functional differences between
wt  and  FMRP  during  differentiation  of  the  NPC  population,  which  was
characterized by a clear metabotropic glutamate response and small response to
elevated K+. Interestingly, most of the FMRP deficient NPCs responded to Ach
stimulation with an intense oscillation. The number of these oscillating cells was
significantly higher in FMRP deficient NPCs compared to wt NPCs. FMRP deficient
NPCs  showed  oscillatory  response  also  to  other  stimuli  such  as  ATP  or  NE
indicating that the alteration is caused by Ca2+ signaling rather than specific Ach
receptor.
   Both the morphological and functional alterations indicate that the absence of
FMRP  plays  a  crucial  role  in  early  neuronal  development.  In  previous  studies
abnormal dedritic spines have been found in several cerebral cortical regions in both
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FXS patients and FMRP deficient mice (Comery et al., 1997; Irwin et al., 2000;
Nimchinsky et al., 2001; Galvez et al., 2003). Also, altered synaptic structures and
functions have been reported in cultured hippocampal neurons of FMRP deficient
mouse (Braun and Segal 2000). It has been suggested that the altered Ca2+ signaling
at the early stages of neuronal maturation correlates with changes in neuronal
morphology and neurotransmitter expression (Ciccolini et al., 2003). This association
between altered Ca2+ signaling and abnormal NPC morphology could well be causal
since the increase in Ca2+ oscillation frequency is known to dramatically increase
expression of certain genes (Dolmetch et al., 1998).  Taken together, these data
suggest that altered Ca2+ signaling in the FMRP deficient NPC population with a
robust mGluR response is likely to contribute to disturbed neurogenesis, synapse
formation, and neural maturation in FXS.
   Stimulation  of  type  I  mGluRs  results  in  FMRP  synthesis,  which  then  leads  to
translation-dependent elongation of dendritic spines (Vanderklish et al., 2002).
Importantly, a main function of FMRP is to act as a translational suppressor (Bagni
and Greenough 2005; Zalfa et al., 2003). Without FMRP expression, neurons are
known to have abnormal dendritic spines because of the lack of FMRP’s suppressive
effects on protein translation (Vanderklish and Edelman 2005). In addition, the
translation-dependent  form of  LTD,  which is  known to  be  induced by mGluR,  has
also been shown to be enhanced in Fmr1 KO mice. Altogether, these findings
indicate that mGluR-dependent translational changes may be exaggerated when
FMRP  is  not  present.  In  agreement  with  this  hypothesis,  Weiler  and  coworkers
(2004) demonstrated that the overall group I mGluR-stimulated translation is
significantly depressed in synaptoneurosomes of the Fmr1 KO mice.
   The high number of cells with oscillatory response in both human and mouse
FMRP deficient NPCs may indicate that the cellular plasticity is altered, particularly
in those cell types which also respond to mGluR activation. Based on our results
obtained by using specific antagonists of glutamate receptors, we suggest that these
cells mainly express mGluR5. This finding is of interest, since disturbances in type I
mGluR signaling has been associated with pathophysiological changes such as
epilepsy, cognitive impairment, and abnormal dendritic spines which all are found
in FXS (Bear et al., 2004).  In addition, a systemic administration of mGluR5
antagonist has been shown to prevent audiogenic seizures in fmr1 KO mice (Yan et
al., 2005). In the future, the type I mGluR antagonists might offer a potential
pharmacological treatment for neurological and psychiatric symptoms in FXS (Bear
et al., 2004). Our study increases the evidence that disruptions in signaling mediated
by group 1 mGluRs are associated with the pathogenesis of FXS.
   The generation of oscillatory signals is a complex phenomenon and is regulated by
various  messengers  (Taylor  and  Thorn  2001)  such  as  G  protein  signaling  (RGS)
protein (Luo et al., 2001). However, the exact mechanisms behind the transmitter
mediated  oscillatory  responses  are  not  well  known.  It  has  been  previously  shown
that mRNA levels of RGS4 are specifically altered in the brain of Fmr1 KO mice
(Tervonen et al., 2005). This change might be involved in the oscillatory responses.
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As a translational regulator, FMRP (Li et al., 2001; Mazroui et al., 2002; Miyashiro et
al., 2003; Zalfa et al., 2003; Bagni & Greenough 2005) could thus regulate the
expression  of  the  proteins  involved  in  the  generation  of  Ca2+ oscillations, which in
turn modify gene expression and direct cells along specific developmental pathways
(Dolmetsch et al. 1998; Taylor and Thorn 2001).
   We also found that the number of newborn cells in the SVZ was significantly
increased in Fmr1 KO brain compared to wt brain. We therefore suggest that the
FMRP deficiency alters the differentiation only in particular cell populations.
Actually, this finding is in line with our observations in Ca2+ imaging studies.
This study demonstrated that NPCs represent a potential model cell type to study
the  mechanisms  behind  the  FXS  when  using  FMRP  deficient  mouse  cells.  In
addition, by using of human NPCs isolated from aborted FXS fetuses it was possible
to study human cells, too. Together with morphological methods, we used Ca2+ -
imaging to study the functional alterations and again, for the first time showed
functional alteration in developing neurons from human origin. Our study shows
that FMRP is important in neuronal development and by using NPCs it is possible to
learn more about the FXS.
6.2 THE ROLE OF NEUROTRANSMITTERS IN DIFFERENTIATION OF
NPCs (II)
A body of evidences indicates that NTs have an important role in the regulation of
NPC differentiation (Hagg, 2005) and thus an impact on the regenerative capacity of
the CNS. Several NTs typically act via GPCRs, and hence are involved in neuronal
plasticity and development. In particular, receptor-mediated changes in intracellular
Ca2+ represent important signaling mechanism in plasticity responses (Ciccolini et
al., 2003). Briefly, this pathway is initiated by the binding of NT to a specific GPCR,
which is coupled with the Gq subtype of G proteins. The resulting activation of
phospholipase C? leads to release of DAG, which then turns on specific isoform(s) of
PKC  and  IP3. The released IP3 causes Ca2+ mobilization from intracellular stores
(Berridge  et  al.,  2000).  This  PKC  -  Ca2+ signaling may take place via MAP-kinase
cascades through several mechanisms, such as the activation of RAF-1, PYK2, SRC,
or transactivation of EGF receptor (Cullen and Lockyer 2002; Pierce et al., 2002).
   In study I, differentiated NPCs were classified into two functional groups based on
their NT responsiveness. Type I NPCs showed robust mGluR5, but small Ca2+
response to elevated K+, while type II cells showed a robust response to elevated K+
and only iGluR glutamate responses instead of mGluR5 response. These results
indicate that NTs may have an important role in the early state of NPCs
differentiation.  To  elucidate  NT  responsiveness  in  more  detail,  in  study  II,  we
challenged 1 – 8 days differentiated mouse wt NPCs with various neurotransmitters
and measured their Ca2+ responses.
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   During the first differentiation day the NPC population was quite homogenous.
Most of NPCs responded to NE, ATP, ACh, and muscarinic agonist OxoM. In earlier
studies, both purinergic and muscarinic ACh signaling have been shown to enhance
the proliferation of NPCs (Mishra et al., 2006; Ma et al., 2000; Williams et al., 2004;
Kotani et al., 2006; Lin et al., 2007) and NE depletion to reduce the proliferation of
NPCs (Kulkarni et al., 2002). However, muscarinic stimulation has been shown to
promote neurogenesis and molecular processes that mediate the early steps of NPCs
specification to neuronal cell lineage, too (Zhao et al., 2003). We suggest that during
the  first  differentiation  days  NPCs  still  have  their  self-renewal  properties  and
respond to NE and ACh stimulations. The positive correlation between ACh/OxoM
responding cells and cells with elevated potassium chloride responses is also in
agreement with the earlier finding. However, there were cell populations which still
responded to ACh after 8 days of differentiation and simultanously showed
neuronal  characteristics,  which  is  in  line  with  previous  studies  which  showed  that
Ach may promote neurogenesis (Zhao et al., 2003).
   When  stimulated  with  neuropeptides  (SP,  NT,  AngII,  and  Ox-A),  a  substantial
proportion of cells responded only to SP stimulation with fast and spiky responses
during the first days of difefrentiation. In previous studies SP has been shown to be
expressed in EGF-generated embryonic mouse striatal primordial cells (Reynolds et
al., 1992). SP has been shown to interact with neurokinin receptor and thus may have
implications in many physiological and pathological conditions such as learning,
memory and pain (Langosch et al., 2005). Interestingly, SP has been speculated to be
involved in the regulation of neuronal maturation (Jacquin et al., 1992). SP is also
known to be released from axons in the bone marrow and stimulate haematopoietic
stem/progenitor cells to proliferate (Rameshwar et al., 2001). In our experiment, the
number of SP responding cells declined during differentiation. A similar trend was
seen in the population of NE responding cells. The positive correlation between SP
and NE responding cells suggests that SP responses occur in cells that also respond
to  NE.  Previously,  both  SP  and  NE  have  been  shown  to  control  the  fate  of
hematopoietic stem cells (Katayama et al., 2006). The negative correlation between
SP responding cells and ACh/OxoM responding cells indicates that in the early stage
of differentiation there are two different cellular subpopulations. This further
suggests that receptor expression patterns are important in the fate determination of
NPCs towards different cell lineages and contribute to the generation of neuronal
diversity in the mature brain (Muotri and Gage, 2006; Kronenberg et al., 2003).
   The more detailed analysis of glutamate responses showed that a significant
proportion of NPCs displayed mGluR5 responses and the trend was similar in
response to NE and SP. Also the number of mGluR5 responding cells declines
during differentiation.  In  previous  studies,  mGluR5 receptor  has  been shown to  be
involved in synaptic plasticity and learning (Simonyi et al., 2005).  MGluR5 has also
a  role  in  the  proliferation  and  survival  of  NPCs in vivo (Di  Giorgi  Gerevini  et  al.,
2004; Gandhi et al., 2008). Previous findings that adult mice lacking mGluR5 have a
reduced number of dividing progenitors in SVZ and that embryonic stem cells (ES)
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express mGluR5 support the hypothesis that mGluR5 regulates the early cell fate
determination (Di Giorgi Gerevini et al., 2004).
   NPCs showing pure ionotropic responses to glutamate were also common. The
same cells had typical robust responses to elevated potassium. These cells with pure
ionotropic response and potassium response were denoted type II cells which
appeared later during the early differentiation period. Spatial analysis showed that
type II cells were most abundantly located in the outer periphery of the neurosphere
migration area. There was a time-dependent inverse correlation between type I and
II  cells,  which  may  indicate  that  type  I  cells  converted  to  type  II  cells  and  then
further  to  neurons.  Our data  suggest  that  prior  to  and during early  differentiation,
NPCs  show  metabotropic  responses  to  a  variety  of  NTs,  but  in  particular  through
mGluR5 receptor. We also further suggest that withdrawal of mitogens causes cell
migration from neurospheres intitiating thus the differentiation program. The
progenitor characteristics progressively decreased and neuronal characteristics
increased during the migration. We suggest that NTs have an important role at this
stage on the fate determination. When the differentiating cells obtain more neuronal
characteristics, they lose mGluR5 responses (and other metabotropic responses), and
start responding through ionotropic glutamate receptors and gain the ability to
respond to depolarization.
Taken together, our data show that the differentiation of NPCs is a dynamic
process  and  NTs  have  an  important  role.  Cells  denoted  type  I  NPCs  showed  both
radial glial and neuronal markers depending on differentiation time and spatial
location relative to the neurosphere. Our results may indicate that metabotropic
glutamate responses and ionotropic responses may be key events in the differention
process.  We  also  suggest  that  other  receptors  such  as  of  ACh  and  NE  play  an
important role in neuronal differentiation. The finding that differentiating NPCs
responded to various NTs in the early stage of differentiation may indicate that the
fate  of  cells  could  be  influenced  by  changes  in  levels  of  NTs  in  that  particular
differentiation stage.
   Our method differentiating NPCs with Ca2+ -imaging let us to characterize the
combinations of neurotransmitter receptors which were present within a single cell
in this study. Compared to immunostaining methods, Ca2+ imaging can gather more
information about the combination of neurotransmitter receptors in individual cells.
6.3  THE  EFFECTS  OF  AD  GENOTYPE  AND  AD-LIKE  NEURAL
ENVIRONMENT ON DIFFERENTIATION OF CULTURED OR
TRANSPLANTED NPCs (III)
In animal models of AD, stem cell transplantation and enhancement of endogenous
neurogenesis  have  been  shown  to  be  beneficial  in  terms  of  improved  cognitive
functions (Blurton-Jones et al. 2009). Therefore, cell transplantation or treatment with
neurogenesis stimulating compounds could be an alternative future therapeutic
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approach also for AD patients. However, AD brain is challenging as an environment
for NPCs and the interplay between transplanted or newly born neurons and the AD
brain  environment  should  be  carefully  analyzed.  As  the  source  of  NPCs  for
transplantation, iPS-derived NPCs are a very potent alternative. However, in the
case the patient carries a disease causing mutation, also iPS-derived NPCs with the
same mutation may display neuronal dysfunction. Such mutations may have an
impact on behavior and fate of transplanted cells and thus the research on the effect
of AD-genotype on transplanted cells is of utmost importance.
   In study III, we elucidated the impact of both the brain A?-burdened environment
and  AD-genotype  on  NPCs in vivo and in vitro. In in vivo experiments, we
transplanted GFP-positive NPCs into the mouse brain and followed the survival,
migration, and differentiation of the transplanted NPC as well as their effects on
hippocampal neurogenesis. Transplanted NPCs survived throughout the study
period  of  8  weeks,  but  importantly,  both  intrinsic  and  extrinsic  AD-like  pathology
changed their differentiation towards a neuronal fate. Three major findings support
this notion. First, a smaller portion of the NPCs transplanted into APdE9-mutant
mice differentiated into astrocytes when compared to NPCs transplanted into wt
mouse brain. Second, APdE9-mutant NPCs differentiated more into Tuj-1 positive
neurons in vitro when  compared  to  wt  controls.  Third,  higher  numbers  of  NPCs
differentiated into GFAP positive astrocytes in wt mouse brain compared to APdE9
mouse  brain.  Our  results  are  opposite  to  previous  findings  which  showed  that
human  NPCs  exposed  to  exogenous  APP  and  transplanted  into  APP23  mice  favor
glial differentiation (Kwak et al., 2006; Marutle et al., 2007). The exact reason for this
discrepancy is not known but different mouse strains may partly explain it. In
addition, human NPCs transplanted into mouse brain may react differently
compared to mouse NPCs and cause inflammatory reactions. Previous studies have
shown variable in vitro results on the effects of A? exposure on neuronal
differentiation (Haughney et al., 2002; Lopez-Toledano and Shelanski 2004; Chen
and Dong 2009), which may probably be due to differences in A? peptide prepations
applied (Lopez-Toledano and Shelanski 2004).
   In our in vitro studies, we used different A? peptide forms to thoroughly explore
the effect of A? on NPCs. We showed that different A? preparations have distinct
effects on differentiating NPCs. A?1-42 decreased  the  amount  of  Tuj-1  positive
neurons  in  APdE9  NPCs  cultures,  but  not  in  wt  NPCs  cultures.  Low  A?1-40
concentration increased the number of Tuj-1 positive neurons in NPCs regardless of
their genotype. The effect of A?1-40 that we found is in agreement with an earlier
report  (Chen  and  Dong  2009).  Also,  our  finding  that  prefibrillized  A?1-42 increased
the number of Tuj-1 positive cells, again regardless of cell genotype, is in agreement
with the report by Lopez-Toledano and coworkers (2004). Overall, our results
indicate that mutant APP and PS1 expressed by NPCs alter the differentiation
potential as well and that different forms of A? peptide have a potential to guide the
differentiation of the NPCs into opposite directions.
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   We also explored the effect of A?1-40 and A?1-42 peptides alone or in combination on
NPCs, and investigated the role of AD-like environment and genotype on the
proliferation and migration of NPCs in vitro and in vivo.  In in vitro experiments, A?1-
42 alone inhibited both proliferation and migration of wt NPCs, which is in
agreement with previous studies (Bondolfi et al., 2002; Haughey et al., 2002). Also,
migration of APdE9 mutant NPCs was reduced after exposure to A?1-42, whereas
exposure to A?1-40 showed opposite effects. In fact, migration of NPCs was increased
in both genotypes after exposure to A?1-40.  Furthermore, the addition of both A?1-40
and A?1-42 together partially reversed the A?1-42 inhibitory effect.
   Our in vivo experiment showed that not only the AD-like environment but also the
genotype of transplanted cells alters the survival and migration of NPCs.
Interestingly,  the  highest  number  of  transplanted NPCs was found in  aged APdE9
mice  transplanted  with  APdE9  NPCs.  Neither  increased  apoptosis  in  younger  wt
mice, nor enhanced proliferation in aged APdE9 mice explained these findings.
Similarly, wt NPCs migrated longer distances transversally when transplanted into
APdE9  mice  and  the  migration  distance  was  further  increased  when  APdE9  NPCs
were transplanted.
   We speculated that overexpression of APP, both in cells and in mouse together
with brain endogenous microenvironment, may stimulate migration of APdE9 NPCs
transplanted into APdE9 mice. In the literature, APP has been shown to be involved
in the migration, neurite outgrowth, proliferation, and differentiation of neurons
(Salinero et al., 2000; Caille et al., 2004; De Strooper and Annaert 2000; Ando et al.,
1999; Marutle et al., 2007). In vitro, A?1-42 alone decreased both proliferation and
migration of NPCs, which is not in line with our in vivo findings. Probably, the brain
endogenous signals enhanced cell mobility and thus higher migration activity was
seen  in  the  AD  brain.  In  several  previous  studies,  AD-mimicking  brain  conditions
and secreted chemokines have been shown to stimulate and guide progenitor cell
migration (Ryu et al., 2009; Tran 2007; Miller et al., 2008; Bhattacharyya et al., 2008b).
?? plaques  could  induce  a  mileau  with  a  local  enhancing  effect  on  migration.  For
example, NPCs may be attracted by A? deposits. However, in agreement with
previous studies by Blurton-Jones et al., (2009), we found limited or negligible
chemotaxis of NPCs towards the A? deposits. On the other hand, the fact that A?1-40
partially reversed the inhibitory effect of A?1-42 on the migrating NPCs in vitro
suggests that A?1-40 is one of the factors contributing to enhanced migration of NPCs
in the APdE9 mouse brain.
This study combined in vivo and in vitro experiments, which actually demonstrated
quite opposite effects. In the in vitro study,  synthetic  A?1-42 clearly inhibited cell
migration and cell survival of differentiating NPCs, while in the in vivo experiment,
the  AD-mimicking  brain  environment  increased  survival  and  migration  of
transplanted NPCs. Variable results between simple in vitro models and in vivo
experiments indicated that for the wider understanding of AD environment, the use
of mouse or other in vivo or ex vivo models are crucially important. Here, we used
double transgenic AD mice which only increase the A?1-42/A?1-40 ratio. An improved
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mouse model for these purposes could be a triple transgenic AD mouse model.
These mice develop both A? plaques and neurofibrillary tangles and therefore more
closely mimic AD pathology (Oddo et al., 2003). Our hypotheses were that the AD-
environment  might  be  toxic  for  transplanted  NPCs  and  therefore  will  reduce  cell
survival. Actually, our in vivo study shows that AD brain was not as unfavorable an
environment for transplanted NPCs as we thought and provides hope that stem cell
transplantation could be one alternative therapeutic approach also for AD patients.
6.4 TRANSPLANTED NPCs STIMULATE ENDOGENOUS
NEUROGENESIS (III)
Transplanted NPCs are thought not only to replace lost neurons and connections,
but also to enhance a brain’s own endogenous repair mechanisms. New neurons are
produced throughout life; however, several factors such as aging and disease affect
endogenous neurogenesis (Lazarov et al., 2010). APdE9 mice have been shown to
have impaired neurogenesis (Taniuchi et al., 2007; Demars et al., 2010). Poorly
functioning neurogenesis has been suggested to contribute to clinical AD (Lazarov
and Marr, 2010). Therefore, supporting the endogenous neurogenesis may be an
attractive target for therapeutic interventions.
   In our experiment, endogenous neurogenesis gradually decreased upon aging. At
6 months of age, significant neurogenesis was seen in both wt and APdE9 mice, but
no difference in the amount of endogenous DCX-positive newly born neurons was
detected between the genotypes. In 9-month-old APdE9 mice, neurogenesis has been
shown to be decreased (Taniuchi et al., 2007); and thereafter, neurogenesis decreases
rapidly with aging. We found few new DCX-positive neurons in wt or APdE9 mice
older  than  9  months.  Interestingly,  a  higher  amount  of  DCX-positive  cells  were
found in hippocampi of the mice where NPCs were injected compared to PBS. There
was not  only  an increase  in  the  number  of  DCX-positive  cells,  but  also  the  neurite
outgrowth of the DCX-positive cells was increased. PBS-injected control mice were
practically  devoid  of  both  DCX-positive  cells  as  well  as  neurite  outgrowth.  Even
though we did not include behavioral analysis in our experiment we suggest that the
NPC transplantation stimulates endogenous neurogenesis, differentiation of NPCs
and might thus have beneficial effects on cognitive functions. In an earlier study,
NPC transplantation has been shown to rescue the memory deficits in triple
transgenic AD mice (Blurton-Jones et al., 2009) via elevation of BDNF levels. BDNF
has also been shown to increase neurogenesis in many studies (Rossi et al., 2006;
Choi et al., 2009; Leng et al., 2009).
   Our finding that NPC transplantation stimulated endogenous neurogenesis even
in old AD mouse brain was unexpected. These results may indicate that even in old
brain, endogenous NPCs still retain their differentiation potential and the reason
why they do not differentiate is the changed brain environment, not the disruption
of the NPCs. Thus, these results support the accepted view of how dominant a role
environmental factors are in the regulation of NPCs and also give hope that by using
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external  stimulus  it  could  be  possible  to  activate  a  patient’s  own  NPCs  for
therapeutic purposes.
6.5 NRF2 MEDIATES THE PROTECTION OF NPCs AGAINST A?
TOXICITY AND PROMOTES ENDOGENOUS NEUROGENESIS (IV)
One of the main mechanisms of neurotoxicity in AD is thought to be OS, which may
damage cellular macromolecules, eventually leading to cell death (Halliwell 2006).
Together  with  inflammatory  processes,  OS  renders  the  AD  brain  quite  an
unfavorable environment for transplanted NPCs. Nrf2 is a transcription factor which
is known to induce expression of hundreds of cytoprotective and detoxication genes.
Both  in  cell  culture  and  in  animal  models  the  induction  or  overexpression  of  Nrf2
has been shown to be protective against neurodegeneration (Shih et al., 2003;
Kanninen et al., 2008; Kanninen et al., 2009). Also vice versa, neurons isolated from
Nrf2 KO mice show increased sensitivity to OS (Lee et al., 2003). One way to
alleviate the effects of OS could be to increase the expression of Nrf2-responsive
genes  and  thus  increase  the  tolerance  against  OS.  Interestingly,  Nrf2  is  known  to
promote neuronal differentiation of neuroblastoma cells (Zhao et al., 2009)
suggesting that in addition to its protective function, Nrf2 may have a role in
neuronal differentiation.
   This study also focused on the investigation of possible impacts of Nrf2 on
proliferation, migration, and differentiation of NPCs as well as its possible protective
effects against A? toxicity. In earlier studies, it has been shown that both
endogenous neurogenesis as well as Nrf2-pathway is impaired in the APdE9 mouse
model of AD (Taniuchi et al., 2007; Kanninen et al., 2008; Choudhry et al., 2010). We
thus hypothesize that loss of these two factors together can have negative impacts on
endogenous neurogenesis and cognitive functions. Thus, supporting the patient´s
own neurogenesis might alleviate memory loss in AD.
   Our results are in strong agreement with previous results showing that Nrf2
overepression protects against A?1-42 toxicity, and that loss of Nrf2 (utilizing Nrf2 -/-
cells) makes the cells more vulnerable against A?1-42 toxicity. As a conclusion, all of
our A? exposure experiments indicated that Nrf2 has a protective role against A?
toxicity. Nrf2 overexpression protected NPCs against A?1-42 toxicity  and  Nrf2
deficency diminished survival, proliferation, migration, and differentiation of NPCs.
   Our results also support the previous findings that Nrf2 plays a role in nerve cell
differentiation. We showed that KA stimulated the neurogenesis with proliferation
and  differentiation  of  NPCs  in  both  wt  and  Nrf2-/-  mice.  However,  the  number  of
Ki67-positive proliferating cells and DCX-positive newly formed neurons was
significantly higher in wt mice compared to Nrf2-/- mice. Similar results were also
detected in in vitro proliferation and differentiation experiments, as Nrf2
overexpressing cells proliferated faster and differentiated more into Tuj-1 positive
neurons  compared  to  either  wt  or  Nrf2  -/-  NPCs.  These in vivo and in vitro results
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suggest that Nrf2 has a crucial role in proliferation and differentiation. However, we
did not detect an ability of Nrf2 to affect cell migration.
   In this study, we also combined both in vivo and in vitro experiments.  These
experiments clearly indicate that Nrf2 has a novel role to stimulate proliferation and
differentiation of NPCs. In the in vitro study, we showed that Nrf2 overexpression
had advantageous effects for survival, proliferation, and neuronal differentiation of
NPCs and that the deficiency of Nrf2 exacerbated A? toxicity. The knowledge that
Nrf2 has both protective and neurogenic function raises the idea that NPCs with
boosted Nrf2 could be beneficial for cell transplantation in the AD brain. NPCs with
boosted Nrf2 could have a protective role against A? toxicity,  and  alleviate  OS
leading to increased cell survival, and make the brain environment more favorable
for endogenous NPCs. In addition, the use of the NPCs with boosted Nrf2 pathway
for transplantation might result in enhanced neuronal differentiation and improved
neuronal recovery. Another therapeutic option to obtain the same benefits could be
the stimulation of endogenous neurogenesis by using small doses of Nrf2 by
introducing small molecules directly into the brain.
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7 Conclusions and summary
The following conclusions can be made based on the presented results.
I
In the first study, we hypothesized that FMRP could be involved in differentiation of
NPCs. Our results show that FMRP deficiency in FXS altered differentiation and
function of NPCs during the early maturation. We demonstrated that FMRP-
deficient neurospheres generate more Tuj-1 positive neurons with fewer, shorter
neurites and smaller cell body volume compared to control. In addition, the number
of GFAP positive astrocytes was decreased due to increased apoptotic cell death in a
FMRP deficient cell population. Functional studies showed that a higher proportion
of FMRP deficient cells responded to neurotransmitters with intense oscillatory Ca2+
response. We also detected a higher proportion of BrdU positive proliferating cells in
SVZ of FMRP deficient mouse brain.
II
In the second study, our hypothesis was that neurotransmitters (NTs) are important
regulators of proliferation and differentiation of NPCs. Several NTs typically
activate ionotropic or G protein-coupled receptors and change the intracellular Ca2+
levels. Therefore, we used Ca2+ -imaging to monitor neurotransmitter responsiveness
at certain stages of NPC differentiation. Our data indicate that differentiation of
NPCs is a dynamic process and the immature and more mature NPCs can be
divided into sub-groups based on their NT responsiveness. At the first
differentiation day, most of the cells showed mGluR5, NE, Ach, and ATP responses.
A small proportion of cells responded also to SP. These NT responses gradually
disappeared when the NPCs matured. After 8 days of differentiation, the cells
showed very robust responses to NMDA involving ionotropic glutamate receptors
and depolarization indicating that the NPCs have differentiated into neurons.
III
In the third study, we investigated whether AD-like environment and AD-genotype
have impacts on the cell fate upon NPC transplantation. Therefore, we dissected out
the contributions of transplanted cell genotype on the behavior of NPCs in AD-like
mouse brain. We showed in in vivo experiments  that  AD  brain  environment
enhanced the transplanted NPC survival, migration, and neuronal differentiation.
Furthermore, if APdE9 NPCs were transplanted into the AD brain they survived and
migrated longer distances compared to wt NPCs. We also showed that transplanted
cells enhanced a mouse’s own neurogenesis even in old AD brain and probably this
could be a way to improve memory deficits. These results suggest that NPC
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transplantation and enhanced neurogenesis could be beneficial also for AD patients
even if using autologous NPCs isolated from patients suffering familiar form of AD.
IV
In  the  fourth  study,  we  hypothesized  that  Nrf2  could  protect  differentiating  NPCs
against  A? toxicity  as  well  as  have  a  role  in  NPC  proliferation,  migration,  and
maturation. To examine the possible roles of Nrf2, we cultured wt, Nrf2
overexpressing, and Nrf2 -/- NPCs and perfomed survival, proliferation,
differentiation, and migration studies with and without A? treatment. In addition, to
examine  the  role  of  Nrf2  in  physiology  of  NPCs  we  did in vivo experiment by
stimulating wt and Nrf2 -/- mice hippocampal neurogenesis by KA. Our results are
in strong agreement with earlier studies where overexpression of Nrf2 protected
NPCs against A?1-42 toxicity and the deficiency of Nrf2 made the cells more sensitive
to A?1-42 toxicity. Furthermore, both in vitro and in vivo experiments showed that
Nrf2 plays a role in nerve cell differentiation and proliferation. NPCs overexpressing
Nrf2 proliferated better and produced a higher number of Tuj-1 positive neurons
compared  to  wt  and  Nrf2  -/-  NPCs.  After  KA  stimulation,  a  higher  number  of
proliferated (Ki67 positive) and DCX positive neurons were seen in wt mice
compared to Nrf2 -/- mice.
To summarize, the presented results demonstrate that NPCs are excellent tools to
study the mechanisms of neuronal differentiation. Culturing NPCs isolated from
normal or genetically modified mice allows studying the mechanisms behind the
normal neurogenesis as well as the effects of genetic mutation. Here, we show that
FMRP has an important role in neuronal development and the deficiency of FMRP
causes the changes in the nerve cells at the early developmental stage. We also
demonstrate that several neurotransmitters have important role during the neuronal
differentiation. For therapeutic purposes, cell replacement therapy by using NPCs
gives hope to recover damages or alleviate the symptoms of various
neurodegenerative diseases. Our results show that AD-linked genotype and
environment have strong impacts on behavior of NPCs. Despite this, transplanted
NPCs survived and migrated better in AD mouse brain compared to normal brain.
We also demonstrate that transplanted NPCs could stimulate endogenous
neurogenesis even in the brains of old AD mice. Furhermore, we show that Nrf2
overexpression could protect differentiating NPCs against A? toxicity  and  even
promote  neuronal  differentiation.  All  of  these  findings  provide  hope  that  cell
replacement therapy could be a suitable treatment also for AD patients.
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